Engineered Sucrose Phosphorylase Variant Enzymes

Abstract

The present invention provides engineered sucrose phosphorylase (SP) enzymes, polypeptides having SP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells containing these polynucleotides and polypeptides. Methods for producing SP enzymes are also provided. The present invention further provides compositions containing SP enzymes and methods for using the engineered SP enzymes. The present invention is particularly useful in the production of pharmaceutical compounds.

Description

[Technical field]

[0001] This application claims priority to U.S. Provisional Application No. 62 / 869,670, filed July 2, 2019, which is incorporated by reference in its entirety for all purposes.

[0002] The present invention provides engineered sucrose phosphorylase (SP) enzymes, polypeptides having SP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides.Methods for producing SP enzymes are also provided.The present invention further provides compositions comprising SP enzymes, methods for using engineered SP enzymes.The present invention is particularly useful in the production of pharmaceutical compounds.

[0003] Reference to a sequence listing, table, or computer program An official copy of the Sequence Listing has been submitted herewith via EFS-Web as an ASCII formatted text file with the filename "CX2-192USP1_ST25.txt", created on July 1, 2019, and 278 kilobytes in size. The Sequence Listing filed via EFS-Web is a part of the present specification and is incorporated herein by reference in its entirety. [Background technology]

[0004] A retrovirus called human immunodeficiency virus (HIV) is the causative agent of acquired immune deficiency syndrome (AIDS), a complex disease involving progressive destruction of the immune system of affected individuals and degeneration of the central and peripheral nervous systems. A common feature of retroviral replication is the reverse transcription of the viral RNA genome by the virus-encoded reverse transcriptase enzyme, which produces a DNA copy of the HIV sequences necessary for viral replication. Some compounds, such as MK-8591, are known reverse transcriptase inhibitors and are useful in the treatment of AIDS and similar diseases. Although there are several compounds known to inhibit HIV reverse transcriptase, there is still a need in the art for additional compounds that are more effective in inhibiting this enzyme, thereby ameliorating the effects of AIDS.

[0005] Nucleoside analogs such as MK-8591 (Merck) are effective inhibitors of HIV reverse transcriptase due to their similarity to the natural nucleosides used in the synthesis of DNA. When reverse transcriptase binds to these analogs, they halt DNA synthesis by inhibiting the processive nature of reverse transcriptase. Stopping the enzyme results in premature termination of the DNA molecule, rendering it ineffective. However, production of nucleoside analogs by standard chemical synthesis techniques can be a challenge due to their chemical complexity. Summary of the Invention [Means for solving the problem]

[0006] The present invention provides engineered sucrose phosphorylase (SP) enzymes, polypeptides having SP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides.Methods for producing SP enzymes are also provided.The present invention further provides compositions comprising SP enzymes and methods for using engineered SP enzymes.The present invention is particularly useful in the production of pharmaceutical compounds.

[0007] The present invention provides an engineered sucrose phosphorylase comprising a polypeptide sequence or a functional fragment thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity to SEQ ID NO:2 and / or 4, wherein the engineered sucrose phosphorylase comprises a polypeptide comprising at least one substitution or set of substitutions in the polypeptide sequence, and the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:2 and / or 4. In some embodiments, the polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2, and the engineered sucrose phosphorylase polypeptide comprises at least one substitution or set of substitutions at one or more positions in the polypeptide sequence selected from 7, 10, 48, 136, 158, 205, 207, 211, 215, 301, 333, 378, 397, and 400, and the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:2. In some embodiments, the engineered sucrose phosphorylase polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2, and the engineered sucrose phosphorylase polypeptide comprises at least one substitution or set of substitutions at one or more positions in the polypeptide sequence selected from 7M, 7V, 7Y, 10W, 48D, 136R, 158R, 205E, 205L, 207L, 211V, 215V, 301G, 333G, 378F, 397L, 397S, 397T, and 400G, and the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:2.In some embodiments, the engineered sucrose phosphorylase polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2, and the engineered sucrose phosphorylase polypeptide comprises at least one substitution or set of substitutions at one or more positions in the polypeptide sequence selected from L7M, L7V, L7Y, Y10W, G48D, P136R, P158R, C205E, C205L, M207L, T211V, I215V, Q301G, A333G, Y378F, V397L, V397S, V397T, and D400G, and the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:2. In some embodiments, the engineered sucrose phosphorylase comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 2. In some embodiments, the engineered sucrose phosphorylase comprises a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 2. In some embodiments, the engineered sucrose phosphorylase comprises a polypeptide sequence having at least 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 2.

[0008] In some embodiments, the present invention provides an engineered sucrose phosphorylase having a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity to SEQ ID NO:4, wherein the engineered sucrose phosphorylase polypeptide is selected from the group consisting of 10 / 215 / 400, 158, 158 / 207 / 215, 158 / 207 / 215 / 301 / 400, 158 / 207 / 215 / 400, 158 / 207 / 400, 158 / 21 The present invention provides an engineered sucrose phosphorylase comprising at least one substitution or set of substitutions at one or more positions in said polypeptide sequence selected from: 1 / 400, 158 / 215 / 301 / 400, 158 / 215 / 400, 158 / 301 / 400, 158 / 400, 205, 207, 207 / 215, 207 / 215 / 400, 207 / 400, 215 / 301, 215 / 400, 242 / 400, 301, 301 / 400, and 400, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO:4.In some embodiments, the present invention relates to an engineered sucrose phosphorylase having a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity to SEQ ID NO:4, wherein the engineered sucrose phosphorylase polypeptide is selected from the group consisting of 10W / 215V / 400G, 158R, 158R / 207L / 215V, 158R / 207L / 215V / 301G / 400G, 158R / 207L / 215V / 400G, 158R / 207L / 400G, 158R / 211V / 400G , 158R / 215V / 301G / 400G, 158R / 215V / 400G, 158R / 301G / 400G, 158R / 400G, 205L, 207L, 207L / 215V, 207L / 215V / 400G, 207L / 400G, 215V / 301G, 215V / 400G, 242G / 400G, 301G, 301G / 400G, and 400G, wherein the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:4.In some embodiments, the present invention relates to an engineered sucrose phosphorylase having a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity to SEQ ID NO:4, wherein the engineered sucrose phosphorylase polypeptide is selected from the group consisting of Y10W / I215V / D400G, P158R, P158R / M207L / I215V, P158R / M207L / I215V / Q301G / D400G, P158R / M207L / I215V / D400G, P158R / M207L / D400G, P158R / T211V / D400G, P158 and R / I215V / Q301G / D400G, P158R / I215V / D400G, P158R / Q301G / D400G, P158R / D400G, C205L, M207L, M207L / I215V, M207L / I215V / D400G, M207L / D400G, I215V / Q301G, I215V / D400G, E242G / D400G, Q301G, Q301G / D400G, and D400G, and wherein the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:70. In some embodiments, the engineered sucrose phosphorylase comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 4. In some embodiments, the engineered sucrose phosphorylase comprises a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 4. In some embodiments, the engineered sucrose phosphorylase comprises a polypeptide sequence having at least 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 4.

[0009] In some additional embodiments, the present invention provides engineered sucrose phosphorylases comprising a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence of at least one engineered sucrose phosphorylase variant listed in Tables 3-1 and / or 4-1.

[0010] In some additional embodiments, the present invention provides engineered sucrose phosphorylases comprising a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:2 and / or 4. In some embodiments, the engineered sucrose phosphorylase comprises a variant engineered sucrose phosphorylase set forth in SEQ ID NO:4.

[0011] The present invention also provides engineered sucrose phosphorylases comprising a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence of at least one engineered sucrose phosphorylase variant set forth in the even-numbered sequences of SEQ ID NOs: 4 to 84.

[0012] The present invention further provides engineered sucrose phosphorylases comprising at least one improved property compared to wild-type Alloscardovia omnicolens sucrose phosphorylase. In some embodiments, the improved property comprises improved activity on a substrate. In some further embodiments, the substrate comprises sucrose or a related disaccharide or other compound and / or inorganic phosphate. In some additional embodiments, the improved property comprises improved production of compound (1) and / or compound (3). In yet some additional embodiments, the engineered sucrose phosphorylase is purified. The present invention also provides compositions comprising at least one engineered sucrose phosphorylase provided herein.

[0013] The present invention also provides a polynucleotide sequence encoding at least one engineered sucrose phosphorylase provided herein. In some embodiments, the polynucleotide sequence encoding at least one engineered sucrose phosphorylase comprises a polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity with SEQ ID NO: 1 and / or 3. In some embodiments, the polynucleotide sequence encoding at least one engineered sucrose phosphorylase comprises a polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 1 and / or 3, and the polynucleotide sequence of the engineered sucrose phosphorylase comprises at least one substitution at one or more positions. In some further embodiments, the polynucleotide sequence encoding at least one engineered sucrose phosphorylase or a functional fragment thereof comprises at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 1 and / or 3. In yet some additional embodiments, the polynucleotide sequence is operably linked to a control sequence. In still some further embodiments, the polynucleotide sequence is codon optimized. In still some additional embodiments, the polynucleotide sequence comprises the polynucleotide sequences set forth in the odd-numbered sequences of SEQ ID NOs: 3-83.

[0014] The present invention also provides an expression vector comprising at least one polynucleotide sequence provided herein.The present invention further provides a host cell comprising at least one expression vector provided herein.In some embodiments, the present invention provides a host cell comprising at least one polynucleotide sequence provided herein.

[0015] The present invention also provides a method for producing engineered sucrose phosphorylase in a host cell, comprising culturing the host cell provided herein under suitable conditions so that at least one engineered sucrose phosphorylase is produced.In some embodiments, the method further comprises recovering at least one engineered sucrose phosphorylase from the culture and / or the host cell.In some additional embodiments, the method further comprises purifying the at least one engineered sucrose phosphorylase. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The present invention provides engineered sucrose phosphorylase (SP) enzymes, polypeptides having SP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides.Methods for producing SP enzymes are also provided.The present invention further provides compositions comprising SP enzymes and methods for using the engineered SP enzymes.The present invention is particularly useful in the production of pharmaceutical compounds.

[0017] Unless otherwise defined, all scientific and technical terms used herein generally have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. In general, the nomenclature used herein and the laboratory procedures of cell culture, molecular genetics, microbiology, organic chemistry, analytical chemistry, and nucleic acid chemistry described below are well known and commonly employed in the art. Such techniques are well known and described in numerous texts and reference materials well known to those skilled in the art. Standard techniques or modifications thereof are used for chemical synthesis and chemical analysis. All patents, patent applications, papers, and publications mentioned herein both above and below are hereby expressly incorporated by reference.

[0018] Any suitable method and material similar or equivalent to the method and material described herein is useful in the practice of the present invention, but some methods and materials are described herein.It should be understood that the present invention is not limited to the specific methodology, protocols, and reagents described, because they may vary according to the context in which they are used by those skilled in the art.Therefore, the terms defined immediately below will be more fully explained with reference to the present invention as a whole.

[0019] It should be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to limit the present invention. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. Numerical ranges include the numbers defining that range. Thus, every numerical range disclosed herein is intended to encompass every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. Similarly, every maximum (or minimum) numerical limitation disclosed herein is also intended to include every lower (or higher) numerical limitation, as if such lower (or higher) numerical limitations were expressly written herein.

[0020] Abbreviations and Definitions Abbreviations used for genetically encoded amino acids are conventional and are as follows: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartate (Asp or D), cysteine ​​(Cys or C), glutamate (Glu or E), glutamine (Gln or Q), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V).

[0021] When three-letter abbreviations are used, amino acids are referred to as having an α-carbon (C α ) can be in either the L- or D-configuration for the α-carbon. For example, "Ala" specifically denotes alanine with no configuration specified for the α-carbon, while "D-Ala" and "L-Ala" specifically denote D-alanine and L-alanine, respectively. When single-letter abbreviations are used, capital letters specifically denote amino acids in the L-configuration for the α-carbon, and lower case letters specifically denote amino acids in the D-configuration for the α-carbon. For example, "A" specifically denotes L-alanine, and "a" specifically denotes D-alanine. When a polypeptide sequence is presented as a series of single-letter or three-letter abbreviations (or mixtures thereof), the sequence is represented in the amino (N) to carboxy (C) direction according to common convention.

[0022] The abbreviations used for genetically coded nucleosides are conventional and are as follows: adenosine (A); guanosine (G); cytidine (C); thymidine (T); and uridine (U). Unless specifically depicted, the abbreviated nucleosides may be either ribonucleosides or 2'-deoxyribonucleosides. Nucleosides may be designated as either ribonucleosides or 2'-deoxyribonucleosides on an individual or aggregate basis. When a nucleic acid sequence is represented as a series of one-letter abbreviations, the sequence is represented in the 5' to 3' direction according to common convention, with no phosphates indicated.

[0023] In reference to the present invention, the technical and scientific terms used in the description herein have the meanings that are commonly understood by those of ordinary skill in the art, unless specifically defined otherwise. Accordingly, the following terms are intended to have the following meanings:

[0024] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "a polypeptide" includes more than one polypeptide.

[0025] Similarly, "comprise," "comprises," "comprising," "include," "includes," and "including" are intended to be interchangeable and not limiting. Thus, as used herein, the term "comprising" and its cognates are used in their inclusive sense (i.e., equivalent to the term "including" and its corresponding cognates).

[0026] It should be further understood that where the description of various embodiments uses the term "comprising," those of ordinary skill in the art will understand that in some specific instances, an embodiment can alternatively be described using the language "consisting essentially of" or "consisting of."

[0027] As used herein, the term "about" refers to an acceptable error for a particular value. In some instances, "about" refers to within 0.05%, 0.5%, 1.0%, or 2.0% of a given value range. In some instances, "about" refers to within 1, 2, 3, or 4 standard deviations of a given value.

[0028] As used herein, "EC" numbers refer to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB) enzyme nomenclature. The IUBMB biochemical classification is a numerical classification system for enzymes based on the chemical reactions they catalyze.

[0029] As used herein, "ATCC" refers to the American Type Culture Collection, whose biorepository collection contains genes and strains.

[0030] As used herein, "NCBI" refers to the National Center for Biological Information and the sequence database therein providing sucrose phosphorylase.

[0031] As used herein, a "sucrose phosphorylase" ("SP") enzyme is an enzyme that catalyzes the conversion of inorganic phosphate and related compounds, such as sucrose and other disaccharides, to fructose and glucose-1-phosphate and / or related compounds. SP enzymes can be naturally occurring, including the wild-type SP enzyme of Alloscardovia omnicolens, or other sucrose phosphorylases or hexosyltransferases found in humans, bacteria, fungi, plants, or other species, or the SP enzymes can be engineered polypeptides produced by human manipulation.

[0032] As used herein, a "phosphopentomutase" ("PPM") enzyme is an enzyme that catalyzes the reversible isomerization of ribose 1-phosphate to ribose 5-phosphate and related compounds, such as deoxyribose phosphate, and analogs of ribose phosphate and deoxyribose phosphate.

[0033] As used herein, "purine nucleoside phosphorylase" ("PNP") enzymes are enzymes that catalyze the reversible phosphorolysis of purine ribonucleosides and related compounds (e.g., deoxyribonucleosides and ribonucleoside and deoxyribonucleoside analogs) to free purine bases and ribose-1-phosphate (and its analogs).

[0034] "Dexyribose phosphate aldolase" and "DERA" are used interchangeably herein and refer to a polypeptide of the lyase family that reversibly breaks or creates carbon-carbon bonds. As used herein, deoxyribose phosphate aldolase includes naturally occurring (wild-type) deoxyribose phosphate aldolases as well as non-naturally occurring engineered polypeptides produced by human engineering. Wild-type deoxyribose phosphate aldolase catalyzes the reversible reaction of 2-deoxy-D-ribose 5-phosphate to D-glyceraldehyde 3-phosphate and acetaldehyde.

[0035] "Protein," "polypeptide," and "peptide" are used interchangeably herein to mean a polymer of at least two amino acids covalently joined by an amide bond, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). Included within this definition are D- and L-amino acids, mixtures of D- and L-amino acids, and polymers containing D- and L-amino acids and mixtures of D- and L-amino acids.

[0036] "Amino acids" may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter symbols.

[0037] As used herein, "hydrophilic amino acid or residue" refers to an amino acid or residue having a side chain that exhibits a hydrophobicity of less than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al. (Eisenberg et al., J. Mol. Biol., 179:125-142

[1984] ). Genetically encoded hydrophilic amino acids include L-Thr (T), L-Ser (S), L-His (H), L-Glu (E), L-Asn (N), L-Gln (Q), L-Asp (D), L-Lys (K), and L-Arg (R).

[0038] As used herein, "acidic amino acid or residue" refers to a hydrophilic amino acid or residue having a side chain that exhibits a pKa value of less than about 6 when the amino acid is included in a peptide or polypeptide. Acidic amino acids typically have a side chain that is negatively charged at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include L-Glu (E) and L-Asp (D).

[0039] As used herein, a "basic amino acid or residue" refers to a hydrophilic amino acid or residue having a side chain that exhibits a pKa value of greater than about 6 when the amino acid is included in a peptide or polypeptide. Basic amino acids typically have a side chain that is positively charged at physiological pH due to association with a hydronium ion. Genetically encoded basic amino acids include L-Arg (R) and L-Lys (K).

[0040] As used herein, "polar amino acid or residue" refers to a hydrophilic amino acid or residue having a side chain that is uncharged at physiological pH but has at least one bond in which the electron pair commonly shared by two atoms is held more closely by one of the atoms. Genetically encoded polar amino acids include L-Asn (N), L-Gln (Q), L-Ser (S), and L-Thr (T).

[0041] As used herein, "hydrophobic amino acid or residue" refers to an amino acid or residue having a side chain that exhibits a hydrophobicity greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al. (Eisenberg et al., J. Mol. Biol., 179:125-142

[1984] ). Genetically encoded hydrophobic amino acids include L-Pro (P), L-Ile (I), L-Phe (F), L-Val (V), L-Leu (L), L-Trp (W), L-Met (M), L-Ala (A), and L-Tyr (Y).

[0042] As used herein, "aromatic amino acid or residue" refers to a hydrophilic or hydrophobic amino acid or residue having a side chain containing at least one aromatic or heteroaromatic ring. Genetically encoded aromatic amino acids include L-Phe (F), L-Tyr (Y), and L-Trp (W). Depending on the pKa of its heteroaromatic nitrogen atom, histidine is classified herein as a hydrophobic or "constrained residue" (see below), although L-His (H) may be classified as a basic or aromatic residue because its side chain contains a heteroaromatic ring.

[0043] As used herein, "constrained amino acid or residue" refers to an amino acid or residue that has a constrained geometry. As used herein, constrained residues include L-Pro (P) and L-His (H). Histidine has a constrained geometry because it has a relatively small imidazole ring. Proline has a constrained geometry because it also has a five-membered ring.

[0044] As used herein, "nonpolar amino acid or residue" refers to a hydrophobic amino acid or residue having a side chain that is uncharged at physiological pH and has a bond in which the electron pair commonly shared by the two atoms is generally held equally by each of the two atoms (i.e., the side chain is nonpolar). Genetically encoded nonpolar amino acids include L-Gly (G), L-Leu (L), L-Val (V), L-Ile (I), L-Met (M), and L-Ala (A).

[0045] As used herein, "aliphatic amino acid or residue" refers to a hydrophobic amino acid or residue having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include L-Ala (A), L-Val (V), L-Leu (L), and L-Ile (I). Note that cysteine ​​(or "L-Cys" or "[C]") is unusual in that it can form disulfide bridges with other L-Cys (C) amino acids or other sulfanyl- or sulfhydryl-containing amino acids. "Cysteine-like residues" include cysteine ​​and other amino acids that contain sulfhydryl moieties available for disulfide bridge formation. The ability of L-Cys (C) (and other amino acids with SH-containing side chains) to exist in a peptide in either the reduced, free -SH form or the oxidized, disulfide-bridged form affects whether L-Cys (C) confers a net hydrophobic or hydrophilic character to the peptide. L-Cys(C) exhibits a hydrophobicity of 0.29 according to the normalized consensus scale of Eisenberg (Eisenberg et al., 1984, supra), although for purposes of the present disclosure, L-Cys(C) should be understood to be categorized in its own unique group.

[0046] As used herein, "small amino acid or residue" refers to an amino acid or residue having a side chain composed of three or fewer carbon and / or heteroatoms in total (excluding the α-carbon and hydrogen). Small amino acids or residues may be further categorized as aliphatic, non-polar, polar, or acidic small amino acids or residues according to the above definitions. Genetically encoded small amino acids include L-Ala (A), L-Val (V), L-Cys (C), L-Asn (N), L-Ser (S), L-Thr (T), and L-Asp (D).

[0047] As used herein, "hydroxyl-containing amino acid or residue" refers to an amino acid that contains a hydroxyl (-OH) moiety. Genetically encoded hydroxyl-containing amino acids include L-Ser (S), L-Thr (T), and L-Tyr (Y).

[0048] As used herein, "polynucleotide" and "nucleic acid" refer to two or more nucleotides covalently linked together. A polynucleotide may be composed entirely of ribonucleotides (i.e., RNA), entirely of 2' deoxyribonucleotides (i.e., DNA), or a mixture of ribonucleotides and 2' deoxyribonucleotides. Nucleosides are typically linked together via standard phosphodiester linkages, but a polynucleotide may contain one or more non-standard linkages. A polynucleotide may be single-stranded or double-stranded, or may contain both single-stranded and double-stranded regions. Moreover, a polynucleotide is typically composed of naturally occurring coding nucleobases (i.e., adenine, guanine, uracil, thymine, and cytosine), but it may contain one or more modified and / or synthetic nucleobases, such as, for example, inosine, xanthine, hypoxanthine, etc. In some embodiments, such modified or synthetic nucleobases are nucleobases that code for an amino acid sequence.

[0049] As used herein, "nucleoside" refers to a glycosylamine that includes a nucleobase (i.e., a nitrogenous base) and a five-carbon sugar (e.g., ribose or deoxyribose). Non-limiting examples of nucleosides include cytidine, uridine, adenosine, guanosine, thymidine, and inosine. In contrast, the term "nucleotide" refers to a glycosylamine that includes a nucleobase, a five-carbon sugar, and one or more phosphate groups. In some embodiments, a nucleoside can be phosphorylated by a kinase to produce a nucleotide.

[0050] As used herein, "nucleoside diphosphate" refers to a glycosylamine that includes a nucleobase (i.e., a nitrogenous base), a five-carbon sugar (e.g., ribose or deoxyribose), and a diphosphate (i.e., pyrophosphate) moiety. In some embodiments herein, "nucleoside diphosphate" is abbreviated as "NDP." Non-limiting examples of nucleoside diphosphate include cytidine diphosphate (CDP), uridine diphosphate (UDP), adenosine diphosphate (ADP), guanosine diphosphate (GDP), thymidine diphosphate (TDP), and inosine diphosphate (IDP). The terms "nucleoside" and "nucleotide" may be used interchangeably in some contexts.

[0051] As used herein, "coding sequence" refers to a portion of a nucleic acid (eg, a gene) that codes for the amino acid sequence of a protein.

[0052] As used herein, the terms "biocatalyst," "biocatalytic," "biotransformation," and "biosynthesis" refer to the use of enzymes to carry out chemical reactions on organic compounds.

[0053] As used herein, "wild-type" and "naturally occurring" refer to forms found in nature. For example, a wild-type polypeptide or polynucleotide sequence is a sequence present in an organism that can be isolated from a natural source and has not been intentionally modified by human manipulation.

[0054] As used herein, "recombinant," "engineered," "variant," and "non-naturally occurring," when used in reference to a cell, nucleic acid, or polypeptide, refer to a material that has been altered in an otherwise non-naturally occurring manner, or that corresponds to the natural or native form of the material. In some embodiments, the cell, nucleic acid, or polypeptide is identical to a naturally occurring cell, nucleic acid, or polypeptide, but is produced or derived by synthetic materials and / or manipulation using recombinant techniques. Non-limiting examples include recombinant cells that express genes not found in the native (non-recombinant) form of the cell, among others, or that express native genes that are otherwise expressed at different levels.

[0055] The term "percent (%) sequence identity" as used herein refers to a comparison in a polynucleotide or polypeptide, and is determined by comparing two optimally aligned sequences over a comparison window, where the portion of the polynucleotide or polypeptide sequence in the comparison window may contain additions or deletions (i.e., gaps) compared to the reference sequence due to optimal alignment of the two sequences. The percentage can be calculated by determining the number of positions where the same nucleic acid base or amino acid residue occurs in both sequences to produce the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to produce the percentage of sequence identity. Alternatively, the percentage can be calculated by determining the number of positions where the same nucleic acid base or amino acid residue occurs in both sequences, or where the nucleic acid base or amino acid residue aligns with gaps to produce the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to produce the percentage of sequence identity. Those skilled in the art will recognize that there are many established algorithms available for aligning two sequences. Optimal alignment of sequences for comparison can be performed by any suitable method, including, but not limited to, by the local homology algorithm of Smith and Waterman (Smith and Waterman, Adv. Appl. Math., 2:482

[1981] ), the homology alignment algorithm of Needleman and Wunsch (Needleman and Wunsch, J. Mol. Biol., 48:443

[1970] ), by the similarity search method of Pearson and Lipman (Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444

[1988] ), by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin software package), or by visual inspection, as known in the art.Examples of algorithms suitable for determining percent sequence identity and sequence similarity include, but are not limited to, the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (see Altschul et al., J. Mol. Biol., 215: 403-410

[1990] ; and Altschul et al., Nucl. Acids Res., 3389-3402

[1977] , respectively). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website. This algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or meet some positive threshold score T when aligned with words of the same length in a database sequence. T is referred to as the neighborhood word score threshold (see Altschul et al., supra). These initial neighborhood word hits act as seeds to initiate searches to find longer HSPs that contain them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. The cumulative score is calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative score. Extension of the word hits in each direction is stopped if the cumulative alignment score falls off its maximum achieved value by an amount X; if the accumulation of one or more negative scoring residue alignments causes the cumulative score to be zero or less; or if the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands.For amino acid sequences, the BLASTP program uses as defaults a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915

[1989] ). Exemplary determinations of sequence alignment and percent sequence identity can be employed using the BESTFIT or GAP programs in the GCG Wisconsin software package (Accelrys, Madison WI) using the default parameters provided.

[0056] As used herein, "reference sequence" refers to a defined sequence used as a basis for sequence and / or activity comparison. A reference sequence can be a subset of a larger sequence, such as a segment of a full-length gene or polypeptide sequence. Generally, a reference sequence is at least 20 nucleotides or amino acid residues long, at least 25 residues long, at least 50 residues long, at least 100 residues long, or the full length of a nucleic acid or polypeptide. Since two polynucleotides or polypeptides each may (1) contain a sequence that is similar between the two sequences (i.e., a portion of the complete sequence), and (2) further contain a sequence that differs between the two sequences, sequence comparison between two (or more) polynucleotides or polypeptides is typically performed by comparing the sequences of the two polynucleotides or polypeptides over a "comparison window" to identify and compare local regions of sequence similarity. In some embodiments, a "reference sequence" may be based on a primary amino acid sequence, but the reference sequence is a sequence that may have one or more changes in the primary sequence.

[0057] As used herein, a "comparison window" refers to a conceptual segment of at least about 20 contiguous nucleotide positions or amino acid residues in which a sequence may be compared to a reference sequence of at least 20 contiguous nucleotides or amino acids, and the portion of the sequence in the comparison window may contain 20 percent or less additions or deletions (i.e., gaps) compared to the reference sequence (no additions or deletions) for optimal alignment of the two sequences. The comparison window may be longer than 20 contiguous residues, including windows of 30, 40, 50, 100, or more, as appropriate.

[0058] As used herein, "corresponding", "with reference to" and "compared to" when used in the context of numbering of a given amino acid or polynucleotide sequence refer to the numbering of the residues of the specified reference sequence when comparing the given amino acid or polynucleotide sequence to the reference sequence. In other words, the residue numbers or residue positions of a given polymer are explicitly indicated with respect to the reference sequence, rather than the actual numerical positions of the residues in the given amino acid or polynucleotide sequence. For example, a given amino acid sequence, such as the amino acid sequence of an engineered sucrose phosphorylase, can be aligned with a reference sequence by introducing gaps to optimize the residue matching between the two sequences. In these cases, although gaps exist, the numbering of the residues in a given amino acid or polynucleotide sequence is done with respect to the reference sequence to which it is aligned.

[0059] As used herein, "substantial identity" refers to a polynucleotide or polypeptide sequence having at least 80 percent sequence identity, at least 85 percent identity, between at least 89-95 percent sequence identity, or more usually at least 99 percent sequence identity relative to a reference sequence over a comparison window of at least 20 residue positions, often over a window of at least 30-50 residues, where the percentage of sequence identity is calculated by comparing the reference sequence to a sequence that contains deletions or additions totaling 20 percent or less of the reference sequence over the comparison window. In some specific embodiments as applied to polypeptides, the term "substantial identity" means that two polypeptide sequences share at least 80 percent sequence identity, preferably at least 89 percent sequence identity, at least 95 percent sequence identity or higher identity (e.g., 99 percent sequence identity) when optimally aligned, e.g., by the programs GAP or BESTFIT using default gap weighting. In some embodiments, residue positions that are not identical in the sequences being compared differ by conservative amino acid substitutions.

[0060] As used herein, "amino acid difference" and "residue difference" refer to the difference in amino acid residue at a position of a polypeptide sequence compared to the amino acid residue at the corresponding position in a reference sequence. In some examples, the reference sequence has a histidine tag, but the numbering is maintained compared to an equivalent reference sequence that does not have a histidine tag. The position of the amino acid difference is generally referred to herein as "Xn", where n refers to the corresponding position in the reference sequence for which the residue difference is based. For example, "residue difference at position X93 compared to SEQ ID NO:4" refers to the difference in amino acid residue at the polypeptide position corresponding to position 93 of SEQ ID NO:4. Thus, if the reference polypeptide of SEQ ID NO:4 has a serine at position 93, then "residue difference at position X93 compared to SEQ ID NO:4" is an amino acid substitution of any residue other than serine at the polypeptide position corresponding to position 93 of SEQ ID NO:4. In most examples herein, a specific amino acid residue difference at a position is referred to as "XnY", where "Xn" designates the corresponding position above, and "Y" is a single letter identifier of the amino acid found in the engineered polypeptide (i.e., the residue that differs from the reference polypeptide). In some examples (e.g., in the tables presented in the examples), the present invention also provides specific amino acid differences, indicated by the conventional designation "AnB", where A is the single-letter identifier of the residue in the reference sequence, "n" is the number of the residue position in the reference sequence, and B is the single-letter identifier of the residue substitution in the sequence of the engineered polypeptide. In some examples, the polypeptides of the present invention may include one or more amino acid residue differences compared to the reference sequence, which are indicated by a list of designated positions where the residue difference exists compared to the reference sequence. In some embodiments, when more than one amino acid can be used at a specific residue position of the polypeptide, the various amino acid residues that can be used are separated by " / " (e.g., X307H / X307P or X307H / P). Slashes can also be used to indicate multiple substitutions within a given variant (i.e., there is more than one substitution in a given sequence, such as in combinatorial variants).In some embodiments, the invention includes engineered polypeptide sequences that contain one or more amino acid differences, including conservative or non-conservative amino acid substitutions. In some additional embodiments, the invention provides engineered polypeptide sequences that contain both conservative and non-conservative amino acid substitutions.

[0061] As used herein, "conservative amino acid substitution" refers to the replacement of a residue with a different residue having a similar side chain, and thus typically involves the replacement of an amino acid in a polypeptide with an amino acid within the same or similar defined class of amino acids. By way of non-limiting example, in some embodiments, an amino acid having an aliphatic side chain is replaced with another aliphatic amino acid (e.g., alanine, valine, leucine, and isoleucine), an amino acid having a hydroxyl side chain is replaced with another amino acid having a hydroxyl side chain (e.g., serine and threonine), an amino acid having an aromatic side chain is replaced with another amino acid having an aromatic side chain (e.g., phenylalanine, tyrosine, tryptophan, and histidine), an amino acid having a basic side chain is replaced with another amino acid having a basic side chain (e.g., lysine and arginine), an amino acid having an acidic side chain is replaced with another amino acid having an acidic side chain (e.g., aspartic acid or glutamic acid), and / or a hydrophobic or hydrophilic amino acid is replaced with another hydrophobic or hydrophilic amino acid, respectively.

[0062] As used herein, "non-conservative substitution" refers to the replacement of an amino acid in a polypeptide with an amino acid having significantly different side chain properties. Non-conservative substitutions may use amino acids between groups rather than within a defined group, and affect (a) the structure of the peptide backbone in the region of substitution (e.g., proline instead of glycine), (b) the charge or hydrophobicity, or (c) the bulk of the side chain. By way of non-limiting example, exemplary non-conservative substitutions may be an acidic amino acid replaced with a basic or aliphatic amino acid, an aromatic amino acid replaced with a small amino acid, and a hydrophilic amino acid replaced with a hydrophobic amino acid.

[0063] As used herein, "deletion" refers to a modification to a polypeptide by removing one or more amino acids from a reference polypeptide. Deletion can include removal of one or more amino acids, two or more amino acids, five or more amino acids, ten or more amino acids, fifteen or more amino acids, or twenty or more amino acids, up to 10% of the total number of amino acids that make up the reference enzyme, or up to 20% of the total number of amino acids, but retains enzyme activity and / or retains improved properties of the engineered sucrose phosphorylase enzyme. Deletion can be directed to the internal and / or terminal parts of the polypeptide. In various embodiments, deletion can include a continuous segment or can be discontinuous. Deletion is typically indicated by "-" in the amino acid sequence.

[0064] As used herein, "insertion" refers to the modification of a polypeptide by the addition of one or more amino acids from a reference polypeptide. The insertion may be an insertion in the internal part of the polypeptide or may be an insertion to the carboxy or amino terminus. As used herein, an insertion includes fusion proteins known in the art. The insertion may be a contiguous segment of amino acids or may be separated by one or more of the amino acids in a naturally occurring polypeptide.

[0065] The term "amino acid substitution set" or "substitution set" refers to a group of amino acid substitutions in a polypeptide sequence compared to a reference sequence. A substitution set can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acid substitutions. In some embodiments, a substitution set refers to a set of amino acid substitutions present in any of the variant sucrose phosphorylases described in the table provided in the examples.

[0066] "Functional fragment" and "biologically active fragment" are used interchangeably herein and refer to a polypeptide that has amino-terminal and / or carboxy-terminal deletions and / or internal deletions, but the remaining amino acid sequence is identical to the corresponding positions in the sequence to which it is compared (e.g., a full-length engineered sucrose phosphorylase of the invention) and retains substantially all of the activity of the full-length polypeptide.

[0067] As used herein, "isolated polypeptide" refers to a polypeptide that is substantially separated from other contaminants (e.g., proteins, lipids, and polynucleotides) that it naturally associates with. This term encompasses polypeptides that have been removed or purified from their naturally occurring environment or expression system (e.g., within a host cell or via in vitro synthesis). Recombinant sucrose phosphorylase polypeptides can be present in cells, in cell culture media, or prepared in various forms, such as lysates or isolated preparations. Thus, in some embodiments, recombinant sucrose phosphorylase polypeptides can be isolated polypeptides.

[0068] As used herein, "substantially pure polypeptide" or "purified protein" refers to a composition in which the polypeptide species is the predominant species present (i.e., more abundant than any other individual macromolecular species in the composition, on a molar or weight basis), and generally, a substantially purified composition is when the species of interest constitutes at least about 50 percent of the macromolecular species present, by mole or percent weight. However, in some embodiments, a composition comprising sucrose phosphorylase comprises sucrose phosphorylase that is less than 50% pure (e.g., about 10%, about 20%, about 30%, about 40%, or about 50%). Generally, a substantially pure sucrose phosphorylase composition constitutes about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, and about 98% or more of all macromolecular species present in the composition, by mole or percent weight. In some embodiments, the target species is purified to essential homogeneity (i.e., contaminant species cannot be detected in the composition by conventional detection methods) and the composition consists essentially of a single macromolecular species. Solvent species, small molecules (<500 Daltons), and elemental ion species are not considered macromolecular species. In some embodiments, the isolated recombinant sucrose phosphorylase polypeptide is a substantially pure polypeptide composition.

[0069] As used herein, "improved enzyme properties" refers to at least one improved property of an enzyme. In some embodiments, the present invention provides engineered sucrose phosphorylase polypeptides that exhibit any improved enzyme properties compared to a reference sucrose phosphorylase polypeptide, and / or a wild-type sucrose phosphorylase polypeptide, and / or another engineered sucrose phosphorylase polypeptide. In this way, the "improvement" level can be determined and compared between various sucrose phosphorylase polypeptides, including wild-type and engineered sucrose phosphorylases. Improved properties include, but are not limited to, properties such as increased protein expression, increased thermoactivity, increased thermostability, increased pH activity, increased stability, increased enzyme activity, increased substrate specificity or affinity, increased specific activity, increased resistance to substrate or end-product inhibition, increased chemical stability, improved chemical selectivity, improved solvent stability, increased resistance to acidic pH, increased resistance to proteolytic activity (i.e., reduced susceptibility to proteolysis), reduced aggregation, increased solubility, and altered temperature profile. In additional embodiments, the term is used to refer to at least one improved property of sucrose phosphorylase enzyme.In some embodiments, the present invention provides engineered sucrose phosphorylase polypeptides that exhibit any improved enzymatic properties compared to reference sucrose phosphorylase polypeptides and / or wild-type sucrose phosphorylase polypeptides, and / or other engineered sucrose phosphorylase polypeptides.Therefore, the "improvement" level can be determined and compared between various sucrose phosphorylase polypeptides, including wild-type and engineered sucrose phosphorylase.

[0070] As used herein, "increased enzyme activity" and "enhanced catalytic activity" refer to improved properties of engineered polypeptides, which may be expressed by an increase in specific activity (e.g., product produced / time / weight protein) compared to a reference enzyme, or an increase in the percent conversion of substrate to product (e.g., the percent conversion of the starting amount of substrate to product in a specified period of time using a specified amount of enzyme). In some embodiments, the terms refer to improved properties of engineered sucrose phosphorylase polypeptides provided herein, which may be expressed by an increase in specific activity (e.g., product produced / time / weight protein) compared to a reference sucrose phosphorylase enzyme, or an increase in the percent conversion of substrate to product (e.g., the percent conversion of the starting amount of substrate to product in a specified period of time using a specified amount of sucrose phosphorylase). In some embodiments, the terms are used in reference to improved sucrose phosphorylase enzymes provided herein. Exemplary methods for determining the enzyme activity of engineered sucrose phosphorylases of the present invention are provided in the Examples. Any property related to enzyme activity, the change of which can lead to increased enzyme activity, can be affected, including the classical enzyme properties of Km, Vmax, or kcat. For example, the improvement in enzymatic activity can be from about 1.1-fold the enzymatic activity of the corresponding wild-type enzyme to as much as 2-fold, 5-fold, 10-fold, 20-fold, 25-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold, or even more, enzymatic activity of a naturally occurring sucrose phosphorylase or another engineered sucrose phosphorylase from which the sucrose phosphorylase polypeptide is derived.

[0071] As used herein, "conversion" refers to the enzymatic conversion (or biotransformation) of a substrate to a corresponding product. "Percent conversion" refers to the percent of a substrate converted to a product within a period of time under specified conditions. Thus, the "enzyme activity" or "activity" of a sucrose phosphorylase polypeptide can be expressed as the "percent conversion" of a substrate to a product within a specified period of time.

[0072] An enzyme with "generalist properties" (or "generalist enzyme") refers to an enzyme that exhibits improved activity with respect to a wide range of substrates compared to the parent sequence. A generalist enzyme does not necessarily have to demonstrate improved activity with respect to every possible substrate. In some embodiments, the present invention provides sucrose phosphorylase variants with generalist properties in that they demonstrate similar or improved activity with respect to a wide range of sterically and electronically diverse substrates compared to the parent gene. In addition, the generalist enzymes provided herein have been engineered to be improved across a wide range of diverse molecules to increase the production of metabolites / products.

[0073] The term "stringent hybridization conditions" as used herein refers to the conditions under which nucleic acid hybrids are stable.As known to those skilled in the art, hybrid stability is reflected by the melting temperature (Tm) of hybrids.Generally, hybrid stability is a function of ionic strength, temperature, G / C content, and the presence of chaotropic agents. Tm values ​​for polynucleotides can be calculated using known methods for predicting melting temperatures (e.g., Baldino et al., Meth. Enzymol., 168:761-777

[1989] ; Bolton et al., Proc. Natl. Acad. Sci. USA 48:1390

[1962] ; Bresslauer et al., Proc. Natl. Acad. Sci. USA 83:8893-8897

[1986] ; Freier et al., Proc. Natl. Acad. Sci. USA 83:9373-9377

[1986] ; Kierzek et al., Biochem., 25:7840-7846

[1986] ; Rychlik et al., Nucl. Acids Res., 18:6409-6412

[1990] ). (See, erratum, Nucl. Acids Res., 19:698

[1991] ; Sambrook et al., supra); Suggs et al., 1981, in Developmental Biology Using Purified Genes, Brown et al. [eds.], pp. 683-693, Academic Press, Cambridge, MA

[1981] ; and Wetmur, Crit. Rev. Biochem. Mol. Biol. 26:227-259

[1991] .) In some embodiments, the polynucleotide encodes a polypeptide disclosed herein and hybridizes under defined conditions, e.g., moderately stringent or highly stringent conditions, to the complement of a sequence encoding an engineered sucrose phosphorylase enzyme of the invention.

[0074] As used herein, "stringency of hybridization" refers to hybridization conditions, such as washing conditions, in the hybridization of nucleic acid. Generally, hybridization reaction is carried out under low stringency conditions, followed by washing at various but higher stringency. The term "moderately stringent hybridization" refers to conditions that allow target DNA to bind to complementary nucleic acid that has about 60% identity to target DNA, preferably about 75% identity, about 85% identity, and about 90% or higher identity to target polynucleotide. Exemplary moderately stringent conditions are equivalent to hybridization in 50% formamide, 5x Denhart's solution, 5x SSPE, 0.2% SDS at 42°C, followed by washing in 0.2x SSPE, 0.2% SDS at 42°C. "High stringency hybridization" generally refers to conditions that are about 10°C or less than the thermal melting temperature Tm determined under solution conditions for a defined polynucleotide sequence. In some embodiments, high stringency conditions refer to conditions that allow hybridization of only those nucleic acid sequences that form stable hybrids at 65°C in 0.018M NaCl (i.e., if a hybrid is not stable at 65°C in 0.018M NaCl, it is not stable under high stringency conditions as contemplated herein). High stringency conditions can be provided, for example, by hybridization under conditions equivalent to 42°C in 50% formamide, 5x Denhart's solution, 5x SSPE, 0.2% SDS, followed by washing at 65°C in 0.1x SSPE, and 0.1% SDS. Another high stringency condition is equivalent to hybridization in 5×SSC containing 0.1% (weight / volume) SDS at 65° C., and washing in 0.1×SSC containing 0.1% SDS at 65° C. Other high stringency conditions, as well as moderately stringent conditions, are described in the references cited above.

[0075] As used herein, "codon optimization" refers to changing the codons of a polynucleotide encoding a protein to those preferentially used in a particular organism so that the encoded protein is efficiently expressed in the organism of interest. Although the genetic code is degenerate in that most amino acids are represented by a few codons, called "synonymous" or "synonymous" codons, it is well known that the codon usage by a particular organism is non-random and biased toward certain codon triplets. This codon usage bias may be higher for a given gene, for genes of common function or ancestral origin, for highly expressed proteins compared to low copy number proteins, and for the total protein-coding region of an organism's genome. In some embodiments, a polynucleotide encoding a sucrose phosphorylase enzyme may be codon-optimized for optimal production in the host organism selected for expression.

[0076] As used herein, "preferred", "optimal" and "high codon usage bias" codons, when used alone or in combination, interchangeably refer to codons that are used in protein coding regions at a higher frequency than other codons that code for the same amino acid. Preferred codons can be determined in relation to codon usage in a single gene, a set of genes of common function or origin, highly expressed genes, codon frequency in the total protein coding region of an entire organism, codon frequency in the total protein coding region of closely related organisms, or a combination thereof. Codons whose frequency increases with gene expression level are typically optimal codons for expression. A variety of methods are known for determining codon frequency (e.g., codon usage, relative synonymous codon usage) and codon preference in a particular organism, and the effective number of codons used in a gene, including multivariate analysis using, for example, cluster analysis or correspondence analysis (see, e.g., GCG CodonPreference, Genetics Computer Group Wisconsin Package; CodonW, Peden, University of Nottingham; McInerney, Bioinform., 14:372-73

[1998] ; Stenico et al., Nucl. Acids Res., 222437-46

[1994] ; and Wright, Gene 87:23-29

[1990] ). Codon usage tables are available for many different organisms (see, e.g., Wada et al., Nucl. Acids Res., 20:2111-2118

[1992] ; Nakamura et al., Nucl. Acids Res., 28:292

[2000] ; Duret, et al., supra; Henaut and Danchin, in Escherichia coli and Salmonella, Neidhardt, et al. (eds.), ASM Press, Washington DC, p. 2047-2066

[1996] ). The data source for obtaining codon usage can rely on any available nucleotide sequence capable of encoding a protein.These datasets include nucleic acid sequences that are actually known to encode expressed proteins (e.g., complete protein coding sequences-CDS), expressed sequence tags (ESTS), or predicted coding regions of genomic sequences (see, e.g., Mount, Bioinformatics: Sequence and Genome Analysis, Chapter 8, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY

[2001] ; Uberbacher, Meth. Enzymol., 266:259-281

[1996] ; and Tiwari et al., Comput. Appl. Biosci., 13:263-270

[1997] ).

[0077] As used herein, "control sequences" includes all components necessary or advantageous for the expression of a polynucleotide and / or polypeptide of the present invention. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter sequence, a signal peptide sequence, an initiation sequence, and a transcription terminator. At a minimum, the control sequence includes a promoter, and a transcription and translation termination signal. The control sequence may be provided with a linker for the purpose of introducing a specific restriction site that facilitates ligation of the control sequence to the coding region of the nucleic acid sequence encoding the polypeptide.

[0078] "Operably linked" is defined herein as a configuration in which a control sequence is suitably positioned relative to a polynucleotide of interest (i.e., in a functional relationship) such that the control sequence directs or regulates expression of the polynucleotide and / or polypeptide of interest.

[0079] "Promoter sequence" refers to a nucleic acid sequence that is recognized by a host cell for expression of a polynucleotide of interest, such as a coding sequence. The promoter sequence contains a transcriptional control sequence that mediates the expression of the polynucleotide of interest. The promoter can be any nucleic acid sequence that exhibits transcriptional activity in a selected host cell, including mutant, truncated, and hybrid promoters, and can be obtained from a gene encoding an extracellular or intracellular polypeptide that is either homologous or heterologous to the host cell.

[0080] The phrase "suitable reaction conditions" refers to conditions in the enzyme conversion reaction solution (e.g., enzyme loading range, substrate loading, temperature, pH, buffer, co-solvent, etc.) that allow the sucrose phosphorylase polypeptide of the present invention to convert the substrate into a desired product compound. Some exemplary "suitable reaction conditions" are provided herein.

[0081] As used herein, "loading," e.g., "compound loading" or "enzyme loading," refers to the concentration or amount of a component in a reaction mixture at the start of the reaction.

[0082] As used herein, a "substrate" in the context of an enzymatic conversion reaction process refers to a compound or molecule that is acted upon by an engineered enzyme (e.g., an engineered sucrose phosphorylase polypeptide) provided herein.

[0083] As used herein, an "increase" in the yield of a product (e.g., a deoxyribose phosphate analog) from a reaction occurs when a particular component (e.g., a sucrose phosphorylase enzyme) present during the reaction produces more product compared to a reaction carried out under the same conditions with the same substrates and other substituents, but not in the absence of the component of interest.

[0084] A reaction is said to be "substantially free" of a particular enzyme if the amount of that enzyme relative to other enzymes involved in catalyzing the reaction is less than about 2%, less than about 1%, or less than about 0.1% (weight / weight).

[0085] As used herein, "fractionating" a liquid (e.g., a culture broth) means applying a separation process (e.g., salting out, column chromatography, size exclusion, and filtration), or a combination of such processes, to provide a solution in which the desired protein comprises a higher percentage of total protein in solution than in the original liquid product.

[0086] As used herein, a "starting composition" refers to any composition that includes at least one substrate. In some embodiments, the starting composition includes any suitable substrate.

[0087] As used herein, "product" in the context of an enzymatic conversion process refers to a compound or molecule that results from the action of an enzyme polypeptide on a substrate.

[0088] As used herein, "equilibration," as used herein, refers to the process of resulting in steady-state concentrations of chemical species in a chemical or enzymatic reaction (e.g., the interconversion of two species A and B), including the interconversion of stereoisomers, as determined by the forward and reverse rate constants of the chemical or enzymatic reaction.

[0089] As used herein, "alkyl" refers to a saturated hydrocarbon group of 1 to 18 (inclusive) carbon atoms, more preferably 1 to 8 (inclusive) carbon atoms, and most preferably 1 to 6 (inclusive) carbon atoms, either straight or branched. Alkyl groups having a designated number of carbon atoms are shown in parentheses (e.g., (C1-C4)alkyl refers to alkyl of 1 to 4 carbon atoms).

[0090] As used herein, "alkenyl" refers to a group of 2 to 12 carbon atoms (inclusive) either straight or branched containing at least one double bond, but optionally containing more than one double bond.

[0091] As used herein, "alkynyl" refers to a group of 2 to 12 carbon atoms (inclusive) either straight or branched containing at least one triple bond, but optionally containing more than one triple bond, and optionally containing one or more double bond moieties.

[0092] As used herein, "heteroalkyl", "heteroalkenyl", and "heteroalkynyl" refer to alkyl, alkenyl, and alkynyl as defined herein, in which one or more carbon atoms are each independently replaced with the same or different heteroatom or heteroatom group. Heteroatoms and / or heteroatom groups with which carbon atoms can be replaced include, but are not limited to, -O-, -S-, -SO-, -NRα-, -PH-, -S(O)-, -S(O)2, -S(O)NRα-, -S(O)2NRα-, and the like, including combinations thereof, where each Rα is independently selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

[0093] As used herein, "alkoxy" refers to the group --ORβ, where Rβ is an alkyl group as defined above, including optionally substituted alkyl groups also as defined herein.

[0094] As used herein, "aryl" refers to an unsaturated aromatic carbocyclic group of 6 to 12 carbon atoms (inclusive) having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). Exemplary aryls include phenyl, pyridyl, naphthyl, and the like.

[0095] As used herein, "amino" refers to the -NH2 group. Substituted amino refers to -NHRδ, NRδRδ, and NRδRδRδ groups, where each Rδ is independently selected from substituted or unsubstituted alkyl, cycloalkyl, cycloheteroalkyl, alkoxy, aryl, heteroaryl, heteroarylalkyl, acyl, alkoxycarbonyl, sulfanyl, sulfinyl, sulfonyl, and the like. Exemplary amino groups include, but are not limited to, dimethylamino, diethylamino, trimethylammonium, triethylammonium, methylsulfonylamino, furanyl-oxy-sulfamino, and the like.

[0096] As used herein, "oxo" refers to =O.

[0097] As used herein, "oxy" refers to the divalent group -O-, which can have a variety of substituents to form different oxy groups including ethers and esters.

[0098] As used herein, "carboxy" refers to --COOH.

[0099] As used herein, "carbonyl" refers to -C(O)-, which can have a variety of substituents to form different carbonyl groups including acids, acid halides, aldehydes, amides, esters, and ketones.

[0100] As used herein, "alkyloxycarbonyl" refers to -C(O)ORε, where Rε is an alkyl group, as defined herein, which can be optionally substituted.

[0101] As used herein, "aminocarbonyl" refers to -C(O)NH2. Substituted aminocarbonyl refers to -C(O)NRδRδ, where the amino group NRδRδ is as defined herein.

[0102] As used herein, "halogen" and "halo" refer to fluoro, chloro, bromo, and iodo.

[0103] As used herein, "hydroxy" refers to --OH.

[0104] As used herein, "cyano" refers to --CN.

[0105] As used herein, "heteroaryl" refers to an aromatic heterocyclic group of 1 to 10 (inclusive) carbon atoms and 1 to 4 (inclusive) heteroatoms selected from oxygen, nitrogen, and sulfur within the ring. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl).

[0106] As used herein, "heteroarylalkyl" refers to an alkyl substituted by a heteroaryl (i.e., a heteroaryl-alkyl group) preferably having 1 to 6 (inclusive) carbon atoms in the alkyl moiety and 5 to 12 (inclusive) ring atoms in the heteroaryl moiety. Such heteroarylalkyl groups are exemplified by pyridylmethyl, and the like.

[0107] As used herein, "heteroarylalkenyl" refers to an alkenyl substituted by a heteroaryl (i.e., a heteroaryl-alkenyl group) preferably having from 2 to 6 (inclusive) carbon atoms in the alkenyl moiety and from 5 to 12 (inclusive) ring atoms in the heteroaryl moiety.

[0108] As used herein, "heteroarylalkynyl" refers to an alkynyl substituted by a heteroaryl (i.e., a heteroaryl-alkynyl group) preferably having from 2 to 6 (inclusive) carbon atoms in the alkynyl moiety and from 5 to 12 (inclusive) ring atoms in the heteroaryl moiety.

[0109] As used herein, "heterocycle," "heterocyclic," and, interchangeably, "heterocycloalkyl" refer to saturated or unsaturated groups having a single ring or multiple condensed rings of 2 to 10 (inclusive) carbon ring atoms and 1 to 4 (inclusive) hetero ring atoms selected from nitrogen, sulfur, or oxygen within the ring. Such heterocyclic groups can have a single ring (e.g., piperidinyl or tetrahydrofuryl) or multiple condensed rings (e.g., indolinyl, dihydrobenzofuran, or quinuclidinyl). Examples of heterocycles include, but are not limited to, furan, thiophene, thiazole, oxazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, pyrrolidine, indoline, and the like.

[0110] As used herein, "membered ring" is meant to include any cyclic structure. The number before the term "membered" indicates the number of skeletal atoms that make up the ring. Thus, for example, cyclohexyl, pyridine, pyran, and thiopyran are six-membered rings, while cyclopentyl, pyrrole, furan, and thiophene are five-membered rings.

[0111] Unless otherwise specified, the positions occupied by hydrogen in the aforementioned groups are replaced by the following radicals: hydroxy, oxo, nitro, methoxy, ethoxy, alkoxy, substituted alkoxy, trifluoromethoxy, haloalkoxy, fluoro, chloro, bromo, iodo, halo, methyl, ethyl, propyl, butyl, alkyl, alkenyl, alkynyl, substituted alkyl, trifluoromethyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, thio, alkylthio, acyl, carboxy, alkoxycarbonyl, carboxamido, substituted carboxamido, alkylsulfonyl, alkylsulfinyl, alkylsulfonylamino, sulfonamido, substituted sulfonamido, cyano, amino, substituted amino, alkylamino, dialkylamino, aminoalkyl, acylamino, amidino, amido and (heterocycle)oxy, and (heterocycle)alkyl; preferred heteroatoms are oxygen, nitrogen, and sulfur. It is understood that when open valences are present in these substituents, they can be further substituted with alkyl, cycloalkyl, aryl, heteroaryl, and / or heterocyclic groups, when these open valences are present at carbon, they can be further substituted with halogens and oxygen, nitrogen, or sulfur linked substituents, and when multiple such open valences are present, these groups can be linked to form rings, either by direct formation of a bond or by forming a bond to a new heteroatom, preferably oxygen, nitrogen, or sulfur.It is further understood that the above substitutions can be made provided that the replacement of a hydrogen with a substituent does not introduce unacceptable instability to the molecules of the invention and is otherwise chemically reasonable.

[0112] As used herein, the term "culturing" refers to growing a population of microbial cells under any suitable conditions (e.g., using a liquid, gel, or solid medium).

[0113] Recombinant polypeptides can be produced using any suitable method known in the art. A gene encoding a wild-type polypeptide of interest can be cloned into a vector, such as a plasmid, and expressed in a desired host, such as E. coli. Variants of recombinant polypeptides can be generated by various methods known in the art. Indeed, there is a wide variety of different mutagenesis techniques well known to those skilled in the art. In addition, mutagenesis kits are also available from many commercial molecular biology suppliers. Methods are available to perform specific substitutions at defined amino acids (site-directed), specific or random mutations in local regions of a gene (region-directed), or random mutagenesis of the entire gene (e.g., saturation mutagenesis). Many suitable methods for generating enzyme variants are known to those skilled in the art, including, but not limited to, site-directed mutagenesis of single-stranded or double-stranded DNA using PCR, cassette mutagenesis, gene synthesis, error-prone PCR, shuffling, and chemical saturation mutagenesis, or any other suitable method known in the art. Mutagenesis and directed evolution methods can be readily applied to enzyme-encoding polynucleotides to generate variant libraries, which can be expressed, screened, and assayed. Any suitable mutagenesis and directed evolution method is useful in the present invention and is well known in the art (e.g., U.S. Pat. Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, 5,837,458, 5,928,905, 6,096,548, 6,117,679, 6,132,970, 6,165,793, 6,170,794, 6,170,795, 6,170,796, 6,170,797 ... , 180,406, 6,251,674, 6,265,201, 6,277,638, 6,287,861, 6,287,862, 6,291,242, 6,297,053, 6 ,303,344, No. 6,309,883, No. 6,319,713, No. 6,319,714, No. 6,323,030, No. 6,326,204, No. 6,335,160, No. 6,335,198, No. 6,No. 344,356, same as No. 6,352,859, same as No. 6,355,484, same as No. 6,358,740, same as No. 6,358,742, same as No. 6,365,377, same as No. 6,365,408, same as No. 6,368,861, same as No. 6,372,497, same as No. 6,337,186 , same as No. 6,376,246, same as No. 6,379,964, same as No. 6,387,702, same as No. 6,391,552, same as No. 6,391,640, same as No. 6,395,547, same as No. 6,406,855, same as No. 6,406,910, same as No. 6,413,745, same as No. 6,413 ,774, same as No. 6,420,175, same as No. 6,423,542, same as No. 6,426,224, same as No. 6,436,675, same as No. 6,444,468, same as No. 6,455,253, same as No. 6,479,652, same as No. 6,482,647, same as No. 6,483,011, same as No. No. 6,484,105, same as No. 6,489,146, same as No. 6,500,617, same as No. 6,500,639, same as No. 6,506,602, same as No. 6,506,603, same as No. 6,518,065, same as No. 6,519,065, same as No. 6,521,453, same as No. 6,528,31 No. 1, same as No. 6,537,746, same as No. 6,573,098, same as No. 6,576,467, same as No. 6,579,678, same as No. 6,586,182, same as No. 6,602,986, same as No. 6,605,430, same as No. 6,613,514, same as No. 6,653,072, same as No. 6,6 No. 86,515, same as No. 6,703,240, same as No. 6,716,631, same as No. 6,825,001, same as No. 6,902,922, same as No. 6,917,882, same as No. 6,946,296, same as No. 6,961,664, same as No. 6,995,017, same as No. 7,024,312, Same as No. 7,058,515, Same as No. 7,105,297, Same as No. 7,148,054, Same as No. 7,220,566, Same as No. 7,288,375, Same as No. 7,384,387, Same as No. 7,421,347, Same as No. 7,430,477, Same as No. 7,462,469, Same as No. 7,534, No. 564, same as No. 7,620,500, same as No. 7,620,502, same as No. 7,629,170, same as No. 7,702,464, same as No. 7,747,391, same as No. 7,747,393, same as No. 7,751,986, same as No. 7,776,598, same as No. 7,783,428, same as No. 7,No. 795,030, same as No. 7,853,410, same as No. 7,868,138, same as No. 7,783,428, same as No. 7,873,477, same as No. 7,873,499, same as No. 7,904,249, same as No. 7,957,912, same as No. 7,981,614, same as No. 8,014,961, same as No. 8,029,988, same as No. 8,048,674, same as No. 8,05 No. 8,001, same as No. 8,076,138, same as No. 8,108,150, same as No. 8,170,806, same as No. 8,224,580, same as No. 8,377,681, same as No. 8,383,346, same as No. 8,457,903, same as No. 8,504,498, same as No. 8,589,085, same as No. 8,762,066, same as No. 8,768,871, same as No. 9,593,326, and all relevant U.S., as well as PCT and non-U.S. counterparts; Ling et al., Anal. Biochem., 254(2):157-78

[1997] ; Dale et al., Meth. Mol. Biol., 57:369-74

[1996] ; Smith, Ann. Rev. Genet., 19:423-462

[1985] ; Botstein et al., Science, 229:1193-1201

[1985] ; Carter, Biochem. J., 237:1-7

[1986] ; Kramer et al., Cell, 38:879-887

[1984] ; Wells et al., Gene, 34:315-323

[1985] ; Minshull et al., Curr. Op. Chem. Biol., 3:284-290

[1999] ; Christians et al., Nat. Biotechnol., 17:259-264

[1999] ; Crameri et al., Nature, 391:288-291

[1998] ; Crameri, et al., Nat. Biotechnol., 15:436-438

[1997] ; Zhang et al., Proc. Nat. Acad. Sci. USA, 94:4504-4509

[1997] ; Crameri et al., Nat. Biotechnol., 14:315-319

[1996] ; Stemmer, Nature, 370:389-391

[1994] ; Stemmer, Proc. Nat. Acad. Sci. USA, 91:10747-10751

[1994] ; WO95 / 22625; WO97 / 0078; WO97 / 35966; WO98 / 27230; WO00 / 42651; WO01 / 75767; and WO2009 / 152336).

[0114] In some embodiments, the enzyme clones obtained after mutagenesis treatment are screened by subjecting the enzyme preparation to a defined temperature (or other assay conditions) and measuring the amount of enzyme activity remaining after heat treatment or other suitable assay conditions.The clones containing the polynucleotides encoding the polypeptides are then isolated from the gene, sequenced to identify nucleotide sequence changes (if any), and used to express the enzyme in a host cell.Measuring enzyme activity from an expression library can be carried out using any suitable method known in the art (e.g., standard biochemical techniques, such as HPLC analysis).

[0115] After the variants are produced, they can be screened for any desired properties (e.g., high or increased activity, or low or reduced activity, increased thermal activity, increased thermostability, and / or acidic pH stability, etc.). In some embodiments, "recombinant sucrose phosphorylase polypeptides" (also referred to herein as "engineered sucrose phosphorylase polypeptides," "variant sucrose phosphorylase enzymes," "sucrose phosphorylase variants," and "sucrose phosphorylase combinatorial variants") are useful.

[0116] As used herein, a "vector" is a DNA construct for introducing a DNA sequence into a cell. In some embodiments, the vector is an expression vector that is operably linked to a suitable control sequence that can cause the expression of the polypeptide encoded by the DNA sequence in a suitable host. In some embodiments, an "expression vector" has a promoter sequence operably linked to a DNA sequence (e.g., a transgene) to drive expression in a host cell, and in some embodiments, also includes a transcription terminator sequence.

[0117] As used herein, the term "expression" includes any step involved in the production of a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses secretion of the polypeptide from the cell.

[0118] As used herein, the term "produce" refers to the production of a protein and / or other compound by a cell. The term encompasses any step involved in the production of a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses the secretion of a polypeptide from a cell.

[0119] As used herein, an amino acid or nucleotide sequence (e.g., a promoter sequence, a signal peptide, a terminator sequence, etc.) is "heterologous" to another sequence to which it is operably linked if the two sequences are not associated in nature. For example, a "heterologous polynucleotide" is any polypeptide that is introduced into a host cell by laboratory techniques, including a polynucleotide that has been removed from the host cell, subjected to laboratory manipulation, and then reintroduced into the host cell.

[0120] As used herein, the terms "host cell" and "host strain" refer to a host suitable for an expression vector comprising the DNA (e.g., a polynucleotide encoding a sucrose phosphorylase variant) provided herein. In some embodiments, the host cell is a prokaryotic or eukaryotic cell that is transformed or transfected by a vector constructed using recombinant DNA techniques known in the art.

[0121] The term "analog" refers to a polypeptide having greater than 70% sequence identity but less than 100% sequence identity (e.g., greater than 75%, greater than 78%, greater than 80%, greater than 83%, greater than 85%, greater than 88%, greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99% sequence identity) with a reference polypeptide. In some embodiments, analog refers to a polypeptide containing one or more non-naturally occurring amino acid residues as well as naturally occurring amino acids, including, but not limited to, homoarginine, ornithine, and norvaline. In some embodiments, analog also includes one or more D-amino acid residues and non-peptide linkages between two or more amino acid residues.

[0122] The term "effective amount" means an amount sufficient to produce a desired result. One of ordinary skill in the art can determine what an effective amount is by using routine experimentation.

[0123] The terms "isolated" and "purified" are used to refer to a molecule (e.g., an isolated nucleic acid, polypeptide, etc.) or other component that has been removed from at least one other component with which it is naturally associated. The term "purified" does not require absolute purity, but rather is intended as a relative definition.

[0124] As used herein, "stereoselectivity" refers to the preferential formation of one stereoisomer over another in a chemical or enzymatic reaction. Stereoselectivity can be partial, where the formation of one stereoisomer is preferred over the other, or complete, where only one stereoisomer is formed. When the stereoisomers are enantiomers, the stereoselectivity is referred to as enantioselectivity, which is the proportion (typically reported as a percentage) of one enantiomer in the sum of the two. This is commonly alternatively reported in the art (typically as a percentage) as the enantiomeric excess ("ee"), calculated according to the formula [major enantiomer - minor enantiomer] / [major enantiomer + minor enantiomer]. When the stereoisomers are diastereoisomers, the stereoselectivity is called diastereoselectivity, which is the proportion (typically reported as a percentage) of one diastereomer in a mixture of two diastereomers, and is commonly alternatively reported as diastereomeric excess ("de"). Enantiomeric excess and diastereomeric excess are types of stereomeric excess.

[0125] As used herein, "regioselectivity," and "regioselective reaction" refer to a reaction in which one direction of making or breaking a bond occurs preferentially over all other possible directions. A reaction can be completely (100%) regioselective, where discrimination is complete, substantially regioselective (at least 75%), where the reaction products at one site are more abundant than the reaction products at the other site, or partially regioselective (x%, where the percentage is set depending on the reaction of interest).

[0126] As used herein, "chemoselectivity" refers to the preferential formation of one product over another in a chemical or enzymatic reaction.

[0127] As used herein, "pH-stable" refers to a sucrose phosphorylase polypeptide that maintains similar activity (e.g., greater than 60% to 80%) compared to the untreated enzyme after exposure to high or low pH (e.g., 4.5-6 or 8-12) for a period of time (e.g., 0.5-24 hours).

[0128] As used herein, "thermostable" refers to a sucrose phosphorylase polypeptide that, after exposure to an elevated temperature (e.g., 40-80°C) for a period of time (e.g., 0.5-24 hours), maintains similar activity (e.g., greater than 60% to 80%) compared to the wild-type enzyme exposed to the same elevated temperature.

[0129] As used herein, "solvent stable" refers to a sucrose phosphorylase polypeptide that maintains similar activity (e.g., greater than 60% to 80%) after exposure to various concentrations (e.g., 5-99%) of a solvent (such as ethanol, isopropyl alcohol, dimethyl sulfoxide [DMSO], tetrahydrofuran, 2-methyltetrahydrofuran, acetone, toluene, butyl acetate, methyl tert-butyl ether, etc.) for a period of time (e.g., 0.5-24 hours) compared to a wild-type enzyme exposed to the same solvent at the same concentration.

[0130] As used herein, "heat and solvent stable" refers to a sucrose phosphorylase polypeptide that is both heat stable and solvent stable.

[0131] As used herein, "optionally" and "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes cases where the event or circumstance occurs and cases where it does not occur. Those of skill in the art will understand that with respect to any molecule described as containing one or more optional substituents, only sterically realistic and / or synthetically feasible compounds are meant to be included.

[0132] As used herein, "optionally substituted" refers to all subsequent modifiers in a term or series of chemical groups. For example, in the term "optionally substituted arylalkyl," the "alkyl" and "aryl" portions of the molecule can be substituted or unsubstituted, and in the series "optionally substituted alkyl, cycloalkyl, aryl, and heteroaryl," the alkyl, cycloalkyl, aryl, and heteroaryl groups can be substituted or unsubstituted independently of the other.

[0133] Detailed Description of the Invention The present invention provides engineered sucrose phosphorylase (SP) enzymes, polypeptides having SP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides.Methods for producing SP enzymes are also provided.The present invention further provides compositions comprising SP enzymes and methods for using the engineered SP enzymes.The present invention is particularly useful in the production of pharmaceutical compounds.

[0134] In some embodiments, the present invention provides enzymes suitable for the production of nucleoside analogs such as MK-8591 (Merck). The present invention was developed to address the potential use of enzymes to produce these nucleoside analogs. In some embodiments, the present invention provides enzymes useful for producing compounds that provide methods for the in vitro enzymatic synthesis of unnatural nucleoside analogs of compound (1). [ka]

[0135] Unnatural nucleosides are essential building blocks for many important classes of drugs, including drugs for the treatment of cancer and viral infections. At least a dozen nucleoside analog drugs are on the market or in clinical trials (Jordheim et al., Nat. Rev. Drug Discovery 12:447-464

[2013] ). One method for producing compound (1) is by purine nucleoside phosphorylase (PNP) catalyzed coupling of ethynyl ribose-1-phosphate, compound (3), and fluoroadenine, compound (2), as shown in Scheme I. [ka]

[0136] Deoxyribose-1-phosphate compounds, such as compound (3), can be difficult to produce. However, the corresponding deoxyribose-5-phosphate compounds can be produced via the coupling of acetaldehyde and D-glyceraldehyde-3-phosphate (or analogs thereof) catalyzed by the enzyme 2-deoxyribose-5-phosphate aldolase (DERA) (Barbas et al., J. Am. Chem. Soc. 112:2013-2014

[1990] ). Once the deoxyribose-5-phosphate analog (4) is formed, it can be converted or isomerized to the corresponding deoxyribose-1-phosphate analog (3) required for Scheme I by the action of the enzyme phosphopentomutase (PPM).

[0137] The equilibrium position of the PNP and PPM reactions shown in Scheme I typically favors the reactants (compounds (2) and (4)) rather than the products (compound (I) and inorganic phosphate). One way to drive the reaction to higher conversion is to remove the inorganic phosphate formed in the coupling step. This can be accomplished by carrying out the reaction of inorganic phosphate with a disaccharide such as sucrose, catalyzed by the enzyme sucrose phosphorylase (SP) (see, for example, U.S. Pat. No. 7,229,797). This reaction, which produces glucose-1-phosphate and fructose, is highly favorable and can drive the entire reaction shown in Scheme II below. [ka]

[0138] Engineered sucrose phosphorylase enzymes with improved properties compared to naturally occurring sucrose phosphorylase can be produced under related process conditions and / or in multienzyme systems, including the system depicted in Scheme III. These engineered SP enzymes can result in improved production of compound (1) and / or have other improved properties. [ka]

[0139] There is a need for engineered SPs with improved activity that operate under typical industrial conditions and / or as part of a multi-enzyme system. The present invention addresses this need and provides engineered SPs suitable for use in these and other reactions under industrial conditions.

[0140] In some embodiments, an engineered SP polypeptide of the disclosure is part of a multienzyme system for producing a compound, such as a nucleoside analog of compound (1). In some embodiments, the engineered SP polypeptide is part of a multienzyme system that includes one or more of the following enzymes: pantothenate kinase, phosphopentomutase, purine nucleoside phosphorylase, alcohol oxidase, aldolase, and / or acetate kinase.

[0141] Engineered SP Polypeptides The present invention provides engineered SP polypeptides, polynucleotides encoding the polypeptides, methods for preparing the polypeptides, and methods for using the polypeptides. When a description refers to a polypeptide, it should be understood that this also describes the polynucleotide encoding the polypeptide. In some embodiments, the present invention provides engineered non-naturally occurring SP enzymes with improved properties compared to wild-type SP enzymes. Any suitable reaction conditions are useful in the present invention. In some embodiments, a method is used to analyze the improved properties of an engineered polypeptide to perform an isomerization reaction. In some embodiments, the reaction conditions are modified with respect to conditions including the concentration or amount of engineered SP, substrates, buffers, solvents, pH, temperature and reaction time, and / or conditions for immobilizing the engineered SP polypeptide to a solid support, as described in detail below and in the examples.

[0142] In some embodiments, additional reaction components or techniques are utilized to supplement the reaction conditions, including taking measures to stabilize or prevent inactivation of enzymes, reduce product inhibition, or shift the equilibrium of the reaction toward the formation of the desired product.

[0143] In some further embodiments, any of the above processes for converting substrate compounds to product compounds may further comprise one or more steps selected from extraction, isolation, purification, crystallization, filtration, and / or lyophilization of the product compounds. Methods, techniques, and protocols for extracting, isolating, purifying, and / or crystallizing products from biocatalytic reaction mixtures produced by the processes provided herein are known to those skilled in the art and / or accessible through routine experimentation. In addition, illustrative methods are provided in the following examples.

[0144] Engineered SP polynucleotides encoding engineered polypeptides, expression vectors, and host cells The present invention provides a polynucleotide that encodes the engineered enzyme polypeptide described herein.In some embodiments, the polynucleotide is operably linked to one or more heterologous regulatory sequences that control gene expression to produce a recombinant polynucleotide that can express the polypeptide.In some embodiments, the expression construct that contains at least one heterologous polynucleotide that encodes the engineered enzyme polypeptide is introduced into a suitable host cell to express the corresponding enzyme polypeptide.

[0145] As will be apparent to those skilled in the art, the availability of protein sequences and knowledge of the codons corresponding to various amino acids provide a description of all polynucleotides capable of encoding the polypeptides of the present invention. Due to the degeneracy of the genetic code, in which the same amino acid is encoded by alternative or synonymous codons, a huge number of nucleic acids can be generated, all of which encode engineered enzyme (e.g., SP) polypeptides. Thus, the present invention provides methods and compositions for producing any and all possible variations of enzyme polynucleotides that can be generated and encode the enzyme polypeptides described herein by selecting combinations based on possible codon choices, and all such variations should be considered as specifically disclosed for any polypeptide described herein, including the amino acid sequences presented in the examples (e.g., various tables).

[0146] In some embodiments, codons are preferably optimized to be utilized by the host cell selected for protein production. For example, preferred codons used in bacteria are typically used for expression in bacteria. Thus, the codon-optimized polynucleotide encoding the engineered enzyme polypeptide contains preferred codons at about 40%, 50%, 60%, 70%, 80%, 90%, or more than 90% of the codon positions in the full-length coding region.

[0147] In some embodiments, the enzyme polynucleotide encodes an engineered polypeptide having an enzymatic activity with the properties disclosed herein, the polypeptide comprising an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to a reference sequence selected from the SEQ ID NOs provided herein, or the amino acid sequence of any variant (e.g., variants provided in the Examples), and one or more residue differences (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residue positions) compared to the amino acid sequence of the reference polynucleotide or any variant disclosed in the Examples. In some embodiments, the reference polypeptide sequence is selected from SEQ ID NOs: 2 and 4.

[0148] In some embodiments, the polynucleotide is capable of hybridizing under high stringency conditions to a reference polynucleotide sequence selected from any of the polynucleotide sequences provided herein or their complements, or a polynucleotide sequence encoding any of the variant enzyme polypeptides provided herein. In some embodiments, the polynucleotide capable of hybridizing under high stringency conditions encodes an enzyme polypeptide that comprises an amino acid sequence having one or more residue differences compared to the reference sequence.

[0149] In some embodiments, the isolated polynucleotide encoding any of the engineered enzyme polypeptides herein is engineered in a variety of ways to facilitate expression of the enzyme polypeptide. In some embodiments, the polynucleotide encoding the enzyme polypeptide comprises an expression vector in which one or more control sequences are present to regulate expression of the enzyme polynucleotide and / or polypeptide. Manipulation of the isolated polynucleotide prior to insertion into the vector may be desirable or necessary depending on the expression vector utilized. Techniques for modifying polynucleotides and nucleic acid sequences using recombinant DNA methods are well known in the art. In some embodiments, the control sequences include promoters, leader sequences, polyadenylation sequences, propeptide sequences, signal peptide sequences, and transcription terminators, among others. In some embodiments, a suitable promoter is selected based on the host cell selection. For bacterial host cells, suitable promoters for directing transcription of the nucleic acid constructs of the disclosure include those derived from the E. coli lac operon, the Streptomyces coelicolor agarase gene (dagA), the Bacillus subtilis levansucrase gene (sacB), the Bacillus licheniformis alpha-amylase gene (amyL), the Bacillus stearothermophilus maltogenic amylase gene (amyM), the Bacillus amyloliquefaciens alpha-amylase gene (amyQ), the Bacillus licheniformis penicillinase gene (penP), the Bacillus subtilis xylA and xylB genes, and prokaryotic beta-lactamase genes (e.g., Villa-Kamaroff et al., Proc. Natl Acad. Sci. USA 75: 3727-3731).

[1978] ), as well as the tac promoter (see, e.g., DeBoer et al., Proc. Natl Acad. Sci. USA 80: 21-25

[1983] ).Exemplary promoters for filamentous fungal host cells include the promoters obtained from the genes for Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid-stable alpha-amylase, Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, and Fusarium oxysporum trypsin-like protease (see, e.g., WO 96 / 00787), as well as the NA2-tpi promoter (Aspergillus niger neutral alpha-amylase and Aspergillus oryzae triosephosphate isomerase gene), and mutant, truncated, and hybrid promoters thereof. Exemplary yeast cell promoters can be derived from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH2 / GAP), and Saccharomyces cerevisiae 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are known in the art (see, for example, Romanos et al., Yeast 8:423-488

[1992] ).

[0150] In some embodiments, the control sequence is also a suitable transcription terminator sequence (i.e., a sequence recognized by a host cell to terminate transcription). In some embodiments, the terminator sequence is operably linked to the 3' end of the nucleic acid sequence encoding the enzyme polypeptide. Any suitable terminator that is functional in the host cell of choice is useful in the present invention. Exemplary transcription terminators for filamentous fungal host cells can be obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease. Exemplary terminators for yeast host cells can be obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are known in the art (see, e.g., Romanos et al., supra).

[0151] In some embodiments, the control sequence is also a suitable leader sequence (i.e., a nontranslated region of an mRNA important for translation by the host cell). In some embodiments, the leader sequence is operably linked to the 5' end of the nucleic acid sequence encoding the enzyme polypeptide. Any suitable leader sequence that is functional in the host cell of choice is useful in the present invention. Exemplary leaders for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, and Aspergillus nidulans triosephosphate isomerase. Suitable leaders for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha factor, and Saccharomyces cerevisiae alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH2 / GAP).

[0152] In some embodiments, the control sequence is also a polyadenylation sequence (i.e., a sequence that is operably linked to the 3' end of a nucleic acid sequence and, upon transcription, is recognized by a host cell as a signal for adding polyadenosine residues to the transcribed mRNA). Any suitable polyadenylation sequence that is functional in the host cell of choice is useful in the present invention. Exemplary polyadenylation sequences for filamentous fungal host cells include, but are not limited to, the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Fusarium oxysporum trypsin-like protease, and Aspergillus niger alpha-glucosidase. Useful polyadenylation sequences for yeast host cells are known (see, e.g., Guo and Sherman, Mol. Cell. Biol., 15:5983-5990

[1995] ).

[0153] In some embodiments, the control sequence is also a signal peptide (i.e., a coding region that encodes an amino acid sequence linked to the amino terminus of a polypeptide which directs the encoded polypeptide into the secretory pathway of a cell). In some embodiments, the 5' end of the coding sequence of the nucleic acid sequence naturally contains a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region that encodes the secreted polypeptide. Alternatively, in some embodiments, the 5' end of the coding sequence contains a signal peptide coding region that is foreign to the coding sequence. Any suitable signal peptide coding region that directs the expressed polypeptide into the secretory pathway of a host cell of choice is useful for expression of an engineered polypeptide. Effective signal peptide coding regions for bacterial host cells are those signal peptide coding regions including, but not limited to, those obtained from the genes of Bacillus NCIB 11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus neutral protease (nprT, nprS, nprM), and Bacillus subtilis prsA. Additional signal peptides are known in the art (see, for example, Simonen and Palva, Microbiol. Rev., 57:109-137

[1993] ). In some embodiments, effective signal peptide coding regions for filamentous fungal host cells include, but are not limited to, signal peptide coding regions from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase, Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase, Humicola insolens cellulase, and Humicola lanuginosa lipase.Useful signal peptides for yeast host cells include, but are not limited to, the signal peptides from the genes for Saccharomyces cerevisiae alpha factor and Saccharomyces cerevisiae invertase.

[0154] In some embodiments, the control sequence is also a propeptide coding region that codes for an amino acid sequence located at the amino terminus of a polypeptide. The resulting polypeptide is referred to as a "proenzyme," "propolypeptide," or "zymogen." A propolypeptide can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region can be obtained from any suitable source, including, but not limited to, the genes for Bacillus subtilis alkaline protease (aprE), Bacillus subtilis neutral protease (nprT), Saccharomyces cerevisiae alpha-factor, Rhizomucor miehei aspartic proteinase, and Myceliophthora thermophila lactase (see, e.g., WO95 / 33836). When both the signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is located next to the amino terminus of the polypeptide, and the signal peptide region is located next to the amino terminus of the propeptide region.

[0155] In some embodiments, regulatory sequences are also utilized. These sequences facilitate the regulation of the expression of the polypeptide relative to the growth of the host cell. An example of a regulatory system is a system that turns the expression of a gene on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. In prokaryotic host cells, suitable regulatory sequences include, but are not limited to, the lac, tac, and trp operator systems. In yeast host cells, suitable regulatory systems include, but are not limited to, the ADH2 system or the GAL1 system. In filamentous fungi, suitable regulatory sequences include, but are not limited to, the TAKA alpha-amylase promoter, the Aspergillus niger glucoamylase promoter, and the Aspergillus oryzae glucoamylase promoter.

[0156] In another aspect, the present invention is directed to recombinant expression vectors that include a polynucleotide encoding an engineered enzyme polypeptide, and one or more expression control regions, such as promoters and terminators, origins of replication, etc., depending on the type of host into which they are introduced. In some embodiments, the various nucleic acids and control sequences described herein are linked together to produce a recombinant expression vector that includes one or more convenient restriction sites to allow for the insertion or replacement of the nucleic acid sequence encoding the enzyme polypeptide at such sites. Alternatively, in some embodiments, the nucleic acid sequences of the present invention are expressed by inserting the nucleic acid sequence or a nucleic acid construct that includes the sequence into a suitable vector for expression. In some embodiments involving the creation of an expression vector, the coding sequence is placed in the vector such that the coding sequence is operably linked to the appropriate control sequence for expression.

[0157] The recombinant expression vector can be any suitable vector (e.g., plasmid or virus) that can be easily subjected to recombinant DNA procedures and cause the expression of the enzyme polynucleotide sequence. The selection of the vector typically depends on the compatibility of the vector with the host cell into which the vector is introduced. The vector can be a linear or closed circular plasmid.

[0158] In some embodiments, the expression vector is an autonomously replicating vector (i.e., a vector that exists as an extrachromosomal entity whose replication is independent of chromosomal replication, such as a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome). The vector may contain any means to ensure self-replication. In some alternative embodiments, the vector is a vector that, when introduced into a host cell, integrates into the genome and replicates together with the chromosome into which it is integrated. Furthermore, in some embodiments, a single vector or plasmid, or two or more vectors or plasmids, and / or transposons, that together contain the total DNA to be introduced into the genome of the host cell, are utilized.

[0159] In some embodiments, the expression vector contains one or more selectable markers that allow easy selection of transformed cells. A "selectable marker" is a gene whose product provides biocide or viral resistance, resistance to heavy metals, prototrophy for auxotrophs, and the like. Examples of bacterial selectable markers include, but are not limited to, the dal genes of Bacillus subtilis or Bacillus licheniformis, or markers that confer antibiotic resistance, such as ampicillin, kanamycin, chloramphenicol, or tetracycline resistance. Suitable markers for yeast host cells include, but are not limited to, ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in filamentous fungal host cells include, but are not limited to, amdS (acetamidase; e.g., from A. nidulans or A. orzyae), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase; e.g., from S. hygroscopicus), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase; e.g., from A. nidulans or A. orzyae), sC (sulfate adenyltransferase), and trpC (anthranilate synthase), and equivalents thereof.

[0160] In another aspect, the present invention provides a host cell comprising at least one polynucleotide encoding at least one engineered enzyme polypeptide of the present invention, the polynucleotide being operably linked to one or more control sequences for expression of the engineered enzyme in the host cell. Host cells suitable for use in expressing the polypeptides encoded by the expression vectors of the present invention are well known in the art and include, but are not limited to, bacterial cells, such as E. coli, Vibrio fluvialis, Streptomyces, and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells, such as Drosophila S2 and Spodoptera Sf9 cells; animal cells, such as CHO, COS, BHK, 293, and Bowes melanoma cells; and plant cells. Exemplary host cells also include various Escherichia coli strains (e.g., W3110 (ΔfhuA) and BL21). Examples of bacterial selectable markers include, but are not limited to, the dal genes of Bacillus subtilis or Bacillus licheniformis, or markers that confer antibiotic resistance, such as ampicillin, kanamycin, chloramphenicol, and / or tetracycline resistance.

[0161] In some embodiments, the expression vectors of the invention contain elements that allow for integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome. In some embodiments involving integration into the host cell genome, the vector relies on the nucleic acid sequence encoding the polypeptide or any other element of the vector to integrate the vector into the genome by homologous or non-homologous recombination.

[0162] In some alternative embodiments, the expression vector contains additional nucleic acid sequences that direct integration into the genome of the host cell by homologous recombination. The additional nucleic acid sequences allow the vector to integrate into the host cell genome at a precise location in the chromosome. To increase the likelihood of integration at a precise location, the integration element preferably contains a sufficient number of nucleotides, for example 100-10,000 base pairs, preferably 400-10,000 base pairs, and most preferably 800-10,000 base pairs, that are highly homologous to the corresponding target sequence to enhance the probability of homologous recombination. The integration element can be any sequence that is homologous to the target sequence in the genome of the host cell. Furthermore, the integration element can be a non-coding or coding nucleic acid sequence. On the other hand, the vector can be integrated into the genome of the host cell by non-homologous recombination.

[0163] In the case of autonomous replication, the vector may further comprise a replication origin that allows the vector to replicate autonomously in the host cell. Examples of bacterial replication origins are P15A ori, or the replication origin of plasmid pBR322, pUC19, pACYCl77 (plasmid having P15A ori), or pACYC184 that allows replication in E. coli, and pUB110, pE194, or pTA1060 that allows replication in Bacillus. Examples of replication origins for use in yeast host cells are the 2 micron replication origin, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The replication origin may be a replication origin that has a mutation that makes its function temperature sensitive in the host cell (see, for example, Ehrlich, Proc. Natl. Acad. Sci. USA 75:1433

[1978] ).

[0164] In some embodiments, more than one copy of the nucleic acid sequence of the present invention is inserted into a host cell to increase the production of gene product.The increase in copy number of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome, or by including an amplifiable selectable marker gene together with the nucleic acid sequence, and the cells containing the amplified copy of the selectable marker gene and thus the additional copy of the nucleic acid sequence can be selected by culturing the cells in the presence of a suitable selectable agent.

[0165] Many of the expression vectors for use in the present invention are commercially available.Suitable commercially available expression vectors include, but are not limited to, p3xFLAGTM expression vector (Sigma-Aldrich Chemicals), which contains the CMV promoter and hGH polyadenylation site for expression in mammalian host cells, and contains the pBR322 origin of replication and ampicillin resistance marker for amplification in E. coli.Other suitable expression vectors include, but are not limited to, pBluescriptII SK(-) and pBK-CMV (Stratagene), and plasmids derived from pBR322 (Gibco BRL), pUC (Gibco BRL), pREP4, pCEP4 (Invitrogen), or pPoly (see, for example, Lathe et al., Gene 57:193-201

[1987] ).

[0166] Thus, in some embodiments, a vector containing at least one variant sucrose phosphorylase coding sequence is transformed into a host cell to allow the propagation of the vector and the expression of the variant sucrose phosphorylase. In some embodiments, the variant sucrose phosphorylase may be post-translationally modified to remove signal peptide, and in some cases, may be cleaved after secretion. In some embodiments, the transformed host cell is cultured in a suitable nutrient medium under conditions that allow the expression of sucrose phosphorylase. Any suitable medium useful for culturing host cells is useful in the present invention, including, but not limited to, minimal or complex medium containing appropriate supplements. In some embodiments, the host cell is grown in HTP medium. Suitable media are available from various commercial sources or may be prepared according to published recipes (e.g., American Type Culture Collection catalogue).

[0167] In another aspect, the present invention provides a host cell comprising a polynucleotide encoding the improved sucrose phosphorylase polypeptide provided herein, the polynucleotide being operably linked to one or more control sequences to express sucrose phosphorylase enzyme in the host cell.The host cell for use in expressing the sucrose phosphorylase polypeptide encoded by the expression vector of the present invention is well known in the art, and includes but is not limited to bacterial cells, such as E.coli, Bacillus megaterium, Lactobacillus kefir, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells, such as Drosophila S2 and Spodoptera Sf9 cells; animal cells, such as CHO, COS, BHK, 293 and Bowes melanoma cells; and plant cells.Appropriate culture medium and growth conditions for the above host cells are well known in the art.

[0168] The polynucleotide for expressing sucrose phosphorylase can be introduced into cells by various methods known in the art.Techniques include electroporation, biolistic particle bombardment, liposome-mediated transfection, calcium chloride transfection, and protoplast fusion, among others.Various methods for introducing polynucleotide into cells are known to those skilled in the art.

[0169] In some embodiments, the host cell is a eukaryotic cell. Suitable eukaryotic host cells include, but are not limited to, fungal cells, algae cells, insect cells, and plant cells. Suitable fungal host cells include, but are not limited to, Ascomycota, Basidiomycota, Deuteromycota, Zygomycota, and Fungi Deuteromycota. In some embodiments, the fungal host cell is a yeast cell and a filamentous fungal cell. The filamentous fungal host cells of the present invention include all filamentous fungal forms of the subdivisions Eumycotina and Oomycota. Filamentous fungi are characterized by vegetative mycelium with cell walls composed of chitin, cellulose, and other complex polysaccharides. The filamentous fungal host cells of the present invention are morphologically distinct from yeast.

[0170] In some embodiments of the invention, the filamentous fungal host cell is selected from the group consisting of Achlya, Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Cephalosporium, Chrysosporium, Cochliobolus, Corynascus, Cryphonectria, Cryptococcus, Coprinus, Coriolus, Diplodia, Endothis, Fusarium, Gibberella, Gliocladium, Humicola, Hypocrea, Myceliophthora, Mucor, Neurospora, Penicilli, and the like. The present invention is directed to cells of any suitable genus and species, including, but not limited to, cells of any of the following genus or species: um, Podospora, Phlebia, Piromyces, Pyricularia, Rhizomucor, Rhizopus, Schizophyllum, Scytalidium, Sporotrichum, Talaromyces, Thermoascus, Thielavia, Trametes, Tolypocladium, Trichoderma, Verticillium, and / or Volvariella, and / or sexual or asexual forms thereof, and their synonyms, basionyms, or taxonomic equivalents thereof.

[0171] In some embodiments of the invention, the host cell is a yeast cell, including, but not limited to, a cell of a Candida, Hansenula, Saccharomyces, Schizosaccharomyces, Pichia, Kluyveromyces, or Yarrowia species. In some embodiments of the invention, the yeast cells are Hansenula polymorpha, Saccharomyces cerevisiae, Saccharomyces carlsbergensis, Saccharomyces diastaticus, Saccharomyces norbensis, Saccharomyces kluyveri, Schizosaccharomyces pombe, Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia kodamae, Pichia membranaefaciens, Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia quercuum, Pichia pijperi, Pichia stipitis, Pichia methanolica, Pichia angusta, Kluyveromyces lactis, Candida albicans, or Yarrowia lipolytica.

[0172] In some embodiments of the invention, the host cells are algal cells, such as Chlamydomonas (e.g., C. reinhardtii) and Phormidium (P. sp. ATCC29409).

[0173] In some other embodiments, the host cell is a prokaryotic cell. Suitable prokaryotic cells include, but are not limited to, gram-positive, gram-negative, and gram-variant bacterial cells.Any suitable bacterial organism is useful in the present invention, including but not limited to Agrobacterium, Alicyclobacillus, Anabaena, Anacystis, Acinetobacter, Acidothermus, Arthrobacter, Azobacter, Bacillus, Bifidobacterium, Brevibacterium, Butyrivibrio, Buchnera, Campestris, Camplyobacter, Clostridium, Corynebacterium, Chromatium, Coprococcus, Escherichia, Enterococcus, Enterobacter, Erwinia, Fusobacterium, Faecalibacterium, Francisella, Flavobacterium, Geobacillus, Haemophilus, Helicobacter, Klebsiella, Lactobacillus, Lactococcus, Ilyobacter, Micrococcus, Microbacterium, Mesorhizobium, Methylobacterium, Methylobacterium, Mycobacterium, Neisseria, Pantoea, Pseudomonas, Prochlorococcus, Rhodobacter, Rhodopseudomonas, Rhodopseudomonas, Roseburia, Rhodospirillum, Rhodococcus, Scenedesmus, Streptomyces, Streptococcus, Synecoccus, Saccharomonospora, Staphylococcus, Serratia, Salmonella, Shigella, Thermoanaerobacterium, Tropheryma, Tularensis, Temecula, Thermosynechococcus, Thermococcus, Ureaplasma, Xanthomonas, Xylella, Yersinia, and Zymomonas.In some embodiments, the host cell is a species of Agrobacterium, Acinetobacter, Azobacter, Bacillus, Bifidobacterium, Buchnera, Geobacillus, Campylobacter, Clostridium, Corynebacterium, Escherichia, Enterococcus, Erwinia, Flavobacterium, Lactobacillus, Lactococcus, Pantoea, Pseudomonas, Staphylococcus, Salmonella, Streptococcus, Streptomyces, or Zymomonas. In some embodiments, the bacterial host strain is non-pathogenic to humans. In some embodiments, the bacterial host strain is an industrial strain. Many industrial bacterial strains are known and suitable in the present invention. In some embodiments of the present invention, the bacterial host strain is an Agrobacterium species (e.g., A.radiobacter, A.rhizogenes, and A.rubi). In some embodiments of the invention, the bacterial host cell is an Arthrobacter species (e.g., A. aurescens, A. citreus, A. globiformis, A. hydrocarboglutamicus, A. mysorens, A. nicotianae, A. paraffineus, A. protophonniae, A. roseoparqffinus, A. sulfureus, and A. ureafaciens). In some embodiments of the invention, the bacterial host cell is a Bacillus species (e.g., B. thuringensis, B. anthracis, B. megaterium, B. subtilis, B. lentus, B. circulans, B. pumilus, B. lautus, B. coagulans, B. brevis, B. firmus, B. alkaophius, B. licheniformis, B. clausii, B. stearothermophilus, B. halodurans, and B. amyloliquefaciens).In some embodiments, the host cell is an industrial Bacillus strain, including but not limited to B. subtilis, B. pumilus, B. licheniformis, B. megaterium, B. clausii, B. stearothermophilus, or B. amyloliquefaciens. In some embodiments, the Bacillus host cell is B. subtilis, B. licheniformis, B. megaterium, B. stearothermophilus, and / or B. amyloliquefaciens. In some embodiments, the bacterial host cell is a Clostridium species (e.g., C. acetobutylicum, C. tetani E88, C. lituseburense, C. saccharobutylicum, C. perfringens, and C. beijerinckii). In some embodiments, the bacterial host cell is a Corynebacterium species (e.g., C. glutamicum and C. acetoacidophilum). In some embodiments, the bacterial host cell is an Escherichia species (e.g., E. coli). In some embodiments, the host cell is Escherichia coli W3110. In some embodiments, the bacterial host cell is an Erwinia species (e.g., E. uredovora, E. carotovora, E. ananas, E. herbicola, E. punctata, and E. terreus). In some embodiments, the bacterial host cell is a Pantoea species (e.g., P. citrea and P. agglomerans). In some embodiments, the bacterial host cell is a Pseudomonas species (e.g., P. putida, P. aeruginosa, P. mevalonii, and P. sp. D-01 10). In some embodiments, the bacterial host cell is a Streptococcus species (e.g., S. equisimiles, S. pyogenes, and S. uberis).In some embodiments, the bacterial host cell is a Streptomyces species (e.g., S. ambofaciens, S. achromogenes, S. avermitilis, S. coelicolor, S. aureofaciens, S. aureus, S. fungidicus, S. griseus, and S. lividans). In some embodiments, the bacterial host cell is a Zymomonas species (e.g., Z. mobilis and Z. lipolytica).

[0174] Many prokaryotic and eukaryotic strains useful in the present invention are readily publicly available from several culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and the Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

[0175] In some embodiments, the host cells are genetically modified to have features that improve protein secretion, protein stability, and / or other properties that are desirable for protein expression and / or secretion. Genetic modification can be achieved by genetic engineering techniques and / or classical microbiology techniques (e.g., chemical or UV mutagenesis and subsequent selection). Indeed, in some embodiments, a combination of recombinant modification and classical selection techniques is used to produce the host cells. Recombinant techniques can be used to introduce, delete, inhibit, or modify nucleic acid molecules to result in increased yields of sucrose phosphorylase variants in the host cells and / or in the culture medium. For example, knocking out Alp1 function results in cells that are protease-deficient, and knocking out pyr5 function results in cells with a pyrimidine-deficient phenotype. In one genetic engineering approach, homologous recombination is used to induce targeted genetic modification by specifically targeting genes in vivo to suppress expression of the encoded proteins. In an alternative approach, siRNA, antisense, and / or ribozyme technologies are useful for inhibiting gene expression. A variety of methods are known in the art for reducing protein expression in cells, including, but not limited to, deletion of all or part of the gene encoding the protein, and site-directed mutagenesis to disrupt expression or activity of the gene product (see, e.g., Chaveroche et al., Nucl. Acids Res., 28:22 e97

[2000] ; Cho et al., Molec. Plant Microbe Interact., 19:7-15

[2006] ; Maruyama and Kitamoto, Biotechnol Lett., 30:1811-1817

[2008] ; Takahashi et al., Mol. Gen. Genom., 272: 344-352

[2004] ; and You et al., Arch. Microbiol.,191:615-622

[2009] , all of which are incorporated herein by reference).Random mutagenesis followed by screening for the desired mutation is also useful (see, e.g., Combier et al., FEMS Microbiol. Lett., 220:141-8

[2003] ; and Firon et al., Eukary. Cell 2:247-55

[2003] , both of which are incorporated by reference).

[0176] Introduction of the vector or DNA construct into the host cell can be accomplished using any suitable method known in the art, including, but not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, PEG-mediated transformation, electroporation, or other common techniques known in the art. In some embodiments, the Escherichia coli expression vector pCK100900i (see U.S. Patent No. 9,714,437, hereby incorporated by reference) is useful.

[0177] In some embodiments, the engineered host cells of the present invention (i.e., "recombinant host cells") are cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying sucrose phosphorylase polynucleotides. Culture conditions, such as temperature, pH, etc., are those previously used for the host cells selected for expression and are well known to those skilled in the art. As mentioned, many standard references and texts are available for the culture and production of many cells, including cells of bacterial, plant, animal (especially mammalian) and archebacterial origin.

[0178] In some embodiments, cells expressing variant sucrose phosphorylase polypeptides of the invention are grown under batch or continuous fermentation conditions. Classical "batch fermentation" is a closed system in which the composition of the medium is set at the beginning of the fermentation and is not subject to artificial changes during the fermentation. A variation of the batch system is "fed-batch fermentation" that is useful in the present invention. In this variation, substrate is added gradually as the fermentation progresses. Fed-batch systems are useful when catabolite repression may inhibit the metabolism of the cells and when it is desirable to limit the amount of substrate in the medium. Batch and fed-batch fermentation are common and well known in the art. "Continuous fermentation" is an open system in which a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned medium is simultaneously removed for processing. Continuous fermentation generally maintains the culture at a constant high density when the cells are primarily in logarithmic growth phase. Continuous fermentation systems strive to maintain steady-state growth conditions. Methods for modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the field of industrial microbiology.

[0179] In some embodiments of the present invention, cell-free transcription / translation systems are useful for producing sucrose phosphorylase. Several systems are commercially available and the methods are well known to those skilled in the art.

[0180] The present invention provides a method for producing a variant sucrose phosphorylase polypeptide or a biologically active fragment thereof. In some embodiments, the method includes providing a host cell transformed with a polynucleotide encoding an amino acid sequence that contains at least about 70% (or at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%) sequence identity with SEQ ID NO: 2 and / or 4 and contains at least one mutation as provided herein; culturing the transformed host cell in a culture medium under conditions in which the host cell expresses the encoded variant sucrose phosphorylase polypeptide; and optionally recovering or isolating the expressed variant sucrose phosphorylase polypeptide and / or recovering or isolating the culture medium containing the expressed variant sucrose phosphorylase polypeptide. In some embodiments, the method further provides that, after expressing the encoded sucrose phosphorylase polypeptide as required, lysing the transformed host cell, and optionally recovering and / or isolating the expressed variant sucrose phosphorylase polypeptide from the cell lysate. The present invention further provides a method for producing variant sucrose phosphorylase polypeptide, comprising culturing the host cell transformed by variant sucrose phosphorylase polypeptide under suitable conditions for producing variant sucrose phosphorylase polypeptide, and recovering variant sucrose phosphorylase polypeptide.Typically, recover or isolate sucrose phosphorylase polypeptide from host cell culture medium, from host cell, or both, using protein recovery techniques well known in the art, including those described herein.In some embodiments, host cell is harvested by centrifugation, disrupted by physical or chemical means, and the crude extract obtained is retained for further purification.Microbial cells employed for expression of proteins can be disrupted by any convenient method, including but not limited to freeze-thaw cycling, sonication, mechanical disruption, and / or the use of cell lysing agents, as well as many other suitable methods well known to those of skill in the art.

[0181] The engineered sucrose phosphorylase enzyme expressed in the host cell can be recovered from the cells and / or culture medium using any one or more of the techniques known in the art for protein purification, including lysozyme treatment, sonication, filtration, salting out, ultracentrifugation, and chromatography, among others. A suitable solution for dissolving and extracting proteins from bacteria, such as E. coli, with high efficiency is commercially available under the trade name CelLytic B™ (Sigma-Aldrich). Thus, in some embodiments, the resulting polypeptide is recovered / isolated and optionally purified by any of a number of methods known in the art. For example, in some embodiments, the polypeptide is isolated from the nutrient medium by conventional procedures, including but not limited to centrifugation, filtration, extraction, spray drying, evaporation, chromatography (e.g., ion exchange, affinity, hydrophobic interaction, chromatofocusing, and size exclusion) or precipitation. In some embodiments, a protein refolding step is used to complete the configuration of the mature protein if desired. In addition, in some embodiments, high performance liquid chromatography (HPLC) is employed in the final purification step. For example, in some embodiments, methods known in the art are useful in the present invention (see, e.g., Parry et al., Biochem. J., 353:117

[2001] ; and Hong et al., Appl. Microbiol. Biotechnol., 73:1331

[2007] , both of which are incorporated herein by reference). Indeed, any suitable purification method known in the art is useful in the present invention.

[0182] Chromatographic techniques for isolating sucrose phosphorylase polypeptides include, but are not limited to, reverse phase chromatography, high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, and affinity chromatography. Conditions for purifying a particular enzyme depend in part on factors such as net charge, hydrophobicity, hydrophilicity, molecular weight, molecular shape, etc., and are known to those skilled in the art.

[0183] In some embodiments, affinity techniques are useful for isolating improved sucrose phosphorylase enzymes. For affinity chromatography purification, any antibody that specifically binds to a sucrose phosphorylase polypeptide may be used. To produce antibodies, various host animals, including but not limited to rabbits, mice, rats, etc., may be immunized by injection with sucrose phosphorylase. The sucrose phosphorylase polypeptide may be attached to a suitable carrier, such as BSA, by a side chain functional group or by a linker attached to a side chain functional group. Various adjuvants, including but not limited to Freund's (complete and incomplete), mineral gels, such as aluminum hydroxide, surfactants, such as lysolecithin, Pluronic® polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants, such as BCG (Bacillus Calmette Guerin) and Corynebacterium parvum, may be used to increase the immune response depending on the host species.

[0184] In some embodiments, sucrose phosphorylase variant is prepared and used in the form of cells expressing enzyme as crude extract or isolated or purified preparation.In some embodiments, sucrose phosphorylase variant is prepared as lyophilisate, powder form (e.g., acetone powder) or prepared as enzyme solution.In some embodiments, sucrose phosphorylase variant is in the form of substantially pure preparation.

[0185] In some embodiments, the sucrose phosphorylase polypeptide is attached to any suitable solid substrate. Solid substrates include, but are not limited to, solid phases, surfaces, and / or membranes. Solid supports include, but are not limited to, organic polymers, such as polystyrene, polyethylene, polypropylene, polyfluoroethylene, polyethyleneoxy, and polyacrylamide, as well as copolymers and grafts thereof. Solid supports can also be inorganic, such as glass, silica, controlled pore glass (CPG), reverse-phase silica, or metal, such as gold or platinum. The substrate configuration can be in the form of beads, spheres, particles, granules, gels, membranes, or surfaces. Surfaces can be planar, substantially planar, or non-planar. Solid supports can be porous or non-porous, and can have expanding or non-expanding features. Solid supports can be configured in the form of wells, depressions, or other containers, vessels, features, or locations. Multiple supports can be configured on an array at various locations addressable for robotic delivery of reagents or by detection methods and / or instruments.

[0186] In some embodiments, immunological methods are used to purify sucrose phosphorylase variants.In one approach, the antibody raised against wild-type or variant sucrose phosphorylase polypeptide (for example, against the polypeptide comprising any of SEQ ID NO: 2 and / or 4, and / or its variant, and / or its immunogenic fragment) using conventional methods is immobilized on beads, mixed with cell culture medium under the condition that variant sucrose phosphorylase binds, and precipitated.In a related approach, immunochromatography is useful.

[0187] In some embodiments, the variant sucrose phosphorylase is expressed as a fusion protein that includes a non-enzyme portion. In some embodiments, the variant sucrose phosphorylase sequence is fused to a purification-facilitating domain. As used herein, the term "purification-facilitating domain" refers to a domain that mediates the purification of the polypeptide to which it is fused. Suitable purification domains include, but are not limited to, metal chelating peptides, histidine-tryptophan modules that allow purification on immobilized metals, sequences that bind glutathione (e.g., GST), hemagglutinin (HA) tags (corresponding to an epitope derived from influenza hemagglutinin protein; see, for example, Wilson et al., Cell 37:767

[1984] ), maltose binding protein sequences, the FLAG epitope utilized in the FLAGS extension / affinity purification system (e.g., the system available from Immunex Corp), and the like. One expression vector contemplated for use in the compositions and methods described herein provides for expression of a fusion protein comprising a polypeptide of the invention fused to a polyhistidine tract separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography; see, e.g., Porath et al., Prot. Exp. Purif., 3:263-281

[1992] ), while the enterokinase cleavage site provides a means of separating the variant sucrose phosphorylase polypeptide from the fusion protein. pGEX vectors (Promega) can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). Generally, such fusion proteins are soluble and can be easily purified from lysed cells by adsorption to ligand-agarose beads (e.g., glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.

[0188] Thus, in another aspect, the invention provides methods of producing an engineered enzyme polypeptide, comprising culturing a host cell capable of expressing a polynucleotide encoding the engineered enzyme polypeptide under conditions suitable for expression of the polypeptide, hi some embodiments, the method further comprises the step of isolating and / or purifying the enzyme polypeptide described herein.

[0189] Suitable culture medium and growth conditions for host cells are well known in the art.Any suitable method for introducing polynucleotide into cells for expression of enzyme polypeptide is contemplated to be useful in the present invention.Suitable techniques include, but are not limited to, electroporation, microprojectile bombardment, liposome-mediated transfection, calcium chloride transfection, and protoplast fusion.

[0190] Various features and embodiments of the present invention are illustrated in the following representative examples, which are intended to be illustrative and not limiting. EXAMPLES

[0191] The following examples, including the experiments and results achieved, are provided for illustrative purposes only and should not be construed as limiting the invention. Indeed, there are a variety of suitable sources for many of the reagents and equipment described below. It is not intended that the invention be limited to any particular source for any reagent or equipment item.

[0192] In the experimental disclosure below, the following abbreviations apply: M (molar); mM (millimolar), uM and μM (micromolar); nM (nanomolar); mol (mole); gm and g (grams); mg (milligrams); ug and μg (micrograms); L and l (liters); ml and mL (milliliters); cm (centimeters); mm (millimeters); um and μm (micrometers); sec. (seconds); min (minutes); h and hr (hours); U (units); MW (molecular weight); rpm (revolutions per minute) / min;psi and PSI (pounds per square inch);℃ (degrees Celsius);RT and rt (room temperature);CV (coefficient of variation);CAM and cam (chloramphenicol);PMBS (polymyxin B sulfate);IPTG (isopropyl beta-Dl-thiogalactopyranoside);LB (lysogenic broth);TB (terrific broth);SFP (shake flask powder);CDS (coding sequence);DNA (deoxyribonucleic acid);RNA (ribonucleic acid);nt (nucleotide; polynucleotide);aa (amino acid; polypeptide);E.coli W3110 (a commonly used laboratory E. coli strain, available from the Coli Genetic Stock Center [CGSC], New Haven, CT); HTP (high throughput); HPLC (high performance liquid chromatography); HPLC-UV (HPLC-ultraviolet-visible detector); 1H NMR (proton nuclear magnetic resonance spectroscopy); FIOPC (fold improvement over positive control); Sigma and Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO; Difco (Difco Laboratories, BD Diagnostic Systems, Detroit, MI); Microfluidics (Microfluidics, Westwood, MA); Life Technologies (Life Technologies, part of Fisher Scientific, Waltham, MA); Amresco (Amresco, LLC, Solon, OH); Carbosynth (Carbosynth, Ltd., Berkshire, UK); Varian (Varian Medical Systems, Palo Alto, CA); Agilent (Agilent Technologies, Inc., Santa Clara, CA); Infors (Infors USA Inc., Annapolis Junction, MD); and Thermotron (Thermotron, Inc., Holland, MI). .

[0193] Example 1 E. coli expression host containing the recombinant sucrose phosphorylase gene The initial sucrose phosphorylase (SP) enzyme used to produce the variants of the present invention was obtained from the wild-type sequence of the species Alloscardovia omnicolens (NCBI reference sequence: WP_021617468.1). The wild-type SP protein sequence was codon-optimized for expression in E. coli, and the DNA was cloned into the expression vector pCK110900 (see FIG. 3 of US Patent Application Publication No. 2006 / 0195947) operably linked to the lac promoter under the control of the lacI repressor. The expression vector also contains a P15a origin of replication and a chloramphenicol resistance gene. The resulting plasmid was transformed into E. coli W3110 using standard methods known in the art. Transformants were isolated by subjecting the cells to chloramphenicol selection as known in the art (see, for example, US Patent No. 8,383,346 and WO2010 / 144103).

[0194] Example 2 Preparation of wet cell pellets containing HTP SPs W3110 E. coli cells were transformed with the respective plasmids containing the SP-encoding genes and plated on LB agar plates containing 1% glucose and 30 μg / ml chloramphenicol (CAM) and grown overnight at 37°C. Monoclonal colonies were picked and inoculated into 180 μl of LB containing 1% glucose and 30 μg / mL chloramphenicol and placed into wells of a 96-well shallow well microtiter plate. The plates were sealed with an O2-permeable seal and the cultures were grown at 30°C, 200 rpm, and 85% humidity. Then, 10 μl of each cell culture was transferred to wells of a 96-well deep well plate containing 390 μl of TB and 30 μg / mL CAM. The deep well plate was sealed with an O2-permeable seal and grown at 30°C, 250 rpm, and 85% humidity until OD 600 The culture was incubated until the β-actin ratio reached 0.6-0.8. The cell culture was then induced by adding isopropyl thioglycoside (IPTG) to a final concentration of 1 mM and incubated overnight at 30°C with shaking at 250 rpm. The cells were then pelleted using centrifugation at 4,000 rpm for 10 min. The supernatant was discarded and the pellet was frozen at -80°C before lysis.

[0195] Example 3 Improved sucrose phosphorylase variant of SEQ ID NO: 2 for producing compound (1) A polynucleotide (SEQ ID NO:1) encoding a polypeptide having sucrose phosphorylase activity of SEQ ID NO:2 was used to generate the engineered polypeptides of Table 3-1. These polypeptides exhibited improved sucrose phosphorylase activity under desired conditions compared to the starting polypeptides (e.g., the ability to produce glucose-1-phosphate from free phosphate and sucrose as measured via the production of compound (1) in the presence of engineered DERA, PPM, and PNP enzymes as shown in Scheme III).

[0196] Engineered polypeptides having amino acid sequences of even-numbered sequence identifiers were generated from the "backbone" amino acid sequence of SEQ ID NO:2 as described below. Directed evolution was initiated from the polynucleotide set forth in SEQ ID NO:1. A library of engineered polypeptides was generated using various well-known techniques (e.g., saturation mutagenesis, recombination of previously identified beneficial amino acid differences) and screened using HTP assays and analytical methods measuring SP activity of the polypeptides. In this case, activity was measured via production of compound (1) in the presence of engineered deoxyribose phosphate aldolase (DERA), phosphopentomutase (PPM), and purine nucleoside phosphorylase (PNP) enzymes as shown in Scheme III above using the analytical methods of Table 3-2. The methods provided herein are useful in the analysis of variants produced using the present invention. However, the methods described herein are not intended to be the only methods applicable to the analysis of variants provided herein and / or produced using the methods provided herein, as other suitable methods are also useful in the present invention.

[0197] High-throughput lysates were prepared as follows: Frozen pellets from the SP variants of clones were prepared as described in Example 2 and lysed with 400 μl of lysis buffer containing 100 mM triethanolamine buffer at pH 7.5, 1 mg / mL lysozyme, and 0.5 mg / mL polymyxin b sulfate (PMBS). The lysis mixture was shaken at room temperature for 2 hours. The plates were then centrifuged at 4000 rpm and 4° C. for 15 minutes.

[0198] Shake flask powder (lyophilized lysate from shake flask cultures) was prepared as follows: Cell cultures of the desired variants were plated onto LB agar plates with 1% glucose and 30 μg / ml CAM and grown overnight at 37°C. A single colony from each culture was transferred to 6 ml of LB with 1% glucose and 30 μg / ml CAM. Cultures were grown at 30°C, 250 rpm for 18 hours and plated at a final OD of 1000 in 250 ml of TB containing 30 μg / ml CAM.600 The cultures were subcultured approximately 1:50 to an OD of 0.05. 600 The culture was grown at 30°C, 250 rpm for approximately 195 min to a pH of 0.6-0.8 and induced with 1 mM IPTG. The culture was then grown at 30°C, 250 rpm for 20 h. The culture was centrifuged at 4000 rpm for 10 min. The supernatant was discarded and the pellet was resuspended in 30 ml of 20 mM triethanolamine, pH 7.5, and lysed using a Microfluidizer® processor system (Microfluidics) at 18,000 psi. The lysate was pelleted (10,000 rpm for 60 min) and the supernatant was frozen and lyophilized.

[0199] Reactions were performed in a tandem 4-enzyme cascade setup with DERA / PPM / PNP / SP enzymes in a total volume of 100 μL in 96-well format in 2 mL deep well plates. Reactions contained DERA, PPM, and PNP as shake flask powders (30 wt% PPM SEQ ID NO:86, 0.5 wt% DERA SEQ ID NO:88, and 0.5 wt% PNPh-4007-PNP SEQ ID NO:90), 26 g / L or 124 mM enantiopure (R)-2-ethynyl-glyceraldehyde substrate, 99 mM F-adenine (0.8 eq.), 186 mM acetaldehyde (40 wt% in isopropanol, 1.5 eq.), 372 mM sucrose (3.0 eq.), 5 mM MnCl2, and 50 mM TEoA, pH 7.5. Reactions were set up as follows: (i) all reaction components except SP were premixed into a single solution, then 90 μL of this solution was aliquoted into each well of a 96-well plate. (ii) 10 μL of SP lysate, prediluted 100-fold using 50 mM TEoA buffer, was then added to the well to initiate the reaction. The reaction plate was heat sealed and incubated at 35°C with shaking at 600 rpm for 18-20 hours.

[0200] The reaction was quenched with 300 μL of a 1:1 mixture of 1M KOH and DMSO. The quenched reaction was shaken on a benchtop shaker for 10 minutes, then centrifuged at 4000 rpm for 5 minutes at 4° C. to pellet any precipitate. Ten microliters of the supernatant was then transferred to a 96-well round-bottom plate pre-filled with 190 μL of 25% MeCN in 0.1M TEoA buffer at pH 7.5. The sample was injected into a Thermo U3000 UPLC system and separated isocratically using an AtlantisT3 C18, 3 μm, 2.1×100 mm column with a mobile phase containing 75:25 water:acetonitrile additionally supplemented with 0.1% TFA as described in Example 3-2. Activity relative to SEQ ID NO:2 was calculated as the peak area of ​​compound (1) formed by the variant enzyme compared to the peak area of ​​compound (1) formed by SEQ ID NO:2 under the specified reaction conditions. [Table 3-1-1] [Table 3-1-2] [Table 3-2]

[0201] Example 4 Improved sucrose phosphorylase variant of SEQ ID NO: 4 for producing compound (1) A polynucleotide (SEQ ID NO: 3) encoding a polypeptide having sucrose phosphorylase activity of SEQ ID NO: 4 was used to generate the engineered polypeptides of Table 4-1. These polypeptides exhibited improved sucrose phosphorylase activity under desired conditions compared to the starting polypeptides (e.g., the ability to produce glucose-1-phosphate from free phosphate and sucrose as measured via the production of compound (1) in the presence of engineered DERA, PPM, and PNP as shown in Scheme III).

[0202] Engineered polypeptides having amino acid sequences of even-numbered sequence identifiers were generated from the "backbone" amino acid sequence of SEQ ID NO:4 as described below. Directed evolution was initiated from the polynucleotide set forth in SEQ ID NO:3. A library of engineered polypeptides was generated using various well-known techniques (e.g., saturation mutagenesis, recombination of previously identified beneficial amino acid differences) and screened using HTP assays and analytical methods to measure SP activity of the polypeptides. In this case, activity was measured via the production of compound (1) in the presence of engineered DERA, PPM, and PNP enzymes as shown in Scheme III, using the analytical methods of Table 3-2. The methods provided herein are useful in the analysis of variants produced using the present invention. However, the methods described herein are not intended to be the only methods applicable to the analysis of variants provided herein and / or produced using the methods provided herein, as other suitable methods are also useful in the present invention.

[0203] High-throughput lysates were prepared as follows: Frozen pellets from the SP variants of clones were prepared as described in Example 2 and lysed with 400 μl of lysis buffer containing 100 mM triethanolamine buffer at pH 7.5, 1 mg / mL lysozyme, and 0.5 mg / mL polymyxin b sulfate (PMBS). The lysis mixture was shaken at room temperature for 2 hours. The plates were then centrifuged at 4000 rpm and 4° C. for 15 minutes.

[0204] Shake flask powder (lyophilized lysate from shake flask cultures) was prepared as follows: Cell cultures of the desired variants were plated onto LB agar plates with 1% glucose and 30 μg / ml CAM and grown overnight at 37°C. A single colony from each culture was transferred to 6 ml of LB with 1% glucose and 30 μg / ml CAM. Cultures were grown at 30°C, 250 rpm for 18 hours and plated at a final OD of 1000 in 250 ml of TB containing 30 μg / ml CAM. 600The cultures were subcultured approximately 1:50 to an OD of 0.05. 600 The culture was grown at 30°C, 250 rpm for approximately 195 min to a pH of 0.6-0.8 and induced with 1 mM IPTG. The culture was then grown at 30°C, 250 rpm for 20 h. The culture was centrifuged at 4000 rpm for 10 min. The supernatant was discarded and the pellet was resuspended in 30 ml of 20 mM triethanolamine, pH 7.5, and lysed using a Microfluidizer® processor system (Microfluidics) at 18,000 psi. The lysate was pelleted (10,000 rpm for 60 min) and the supernatant was frozen and lyophilized.

[0205] Reactions were performed in a tandem 4-enzyme cascade setup with DERA / PPM / PNP / SP enzymes in a total volume of 100 μL in a 96-well format in 2 mL deep well plates. Reactions contained DERA, PPM, and PNP as shake flask powders (30 wt% PPM SEQ ID NO:86, 0.5 wt% DERA SEQ ID NO:88, and 0.5 wt% PNP SEQ ID NO:90), 26 g / L or 124 mM enantiopure (R)-2-ethynyl-glyceraldehyde substrate, 99 mM F-adenine (0.8 eq.), 186 mM acetaldehyde (40 wt% in isopropanol, 1.5 eq.), 372 mM sucrose (3.0 eq.), 5 mM MnCl2, and 50 mM TEoA, pH 7.5. Reactions were set up as follows: (i) all reaction components except SP were premixed into a single solution, then 90 μL of this solution was aliquoted into each well of a 96-well plate. (ii) 10 μL of SP lysate, prediluted 100-fold using 50 mM TEoA buffer, was then added to the well to initiate the reaction. The reaction plate was heat sealed and incubated at 35°C with shaking at 600 rpm for 18-20 hours.

[0206] The reaction was quenched with 300 μL of a 1:1 mixture of 1M KOH and DMSO. The quenched reaction was shaken on a benchtop shaker for 10 minutes, then centrifuged at 4000 rpm for 5 minutes at 4° C. to pellet any precipitate. Ten microliters of the supernatant was then transferred to a 96-well round-bottom plate pre-filled with 190 μL of 25% MeCN in 0.1M TEoA buffer at pH 7.5. The sample was injected into a Thermo U3000 UPLC system and separated isocratically using an AtlantisT3 C18, 3 μm, 2.1×100 mm column with a mobile phase containing 75:25 water:acetonitrile additionally supplemented with 0.1% TFA as described in Example 3-2. Activity relative to SEQ ID NO:4 was calculated as the peak area of ​​compound (1) formed by the variant enzyme compared to the peak area of ​​compound (1) formed by SEQ ID NO:4 under the specified reaction conditions. [Table 4-1]

[0207] All publications, patents, patent applications, and other documents cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document was individually indicated to be incorporated by reference for all purposes.

[0208] While various specific embodiments have been illustrated and described, it will be recognized that various changes can be made without departing from the spirit and scope of the invention.

Claims

1. An engineered sucrose phosphorylase comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:2 or a functional fragment thereof, wherein the polypeptide sequence of the engineered sucrose phosphorylase comprises at least one substitution or set of substitutions at one or more amino acid positions in the polypeptide sequence selected from 397 and 158, the engineered sucrose phosphorylase comprises V397S, V397T, V397L, or P158R, the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:2, and the engineered sucrose phosphorylase or functional fragment thereof is selected from the wild-type Alloscardovia spp. omnicolens sucrose phosphorylase, the engineered sucrose phosphorylase comprising improved activity on a substrate selected from the group consisting of sucrose, sucrose-related disaccharides, and / or inorganic phosphate.

2. The engineered sucrose phosphorylase of claim 1, wherein the polypeptide sequence of the engineered sucrose phosphorylase further comprises at least one substitution or set of substitutions at one or more amino acid positions in the polypeptide sequence selected from 7, 10, 48, 136, 205, 207, 211, 215, 301, 333, 378, and 400, and the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:

2.

3. The polypeptide sequence of the engineered sucrose phosphorylase has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 4, and the polypeptide sequence of the engineered sucrose phosphorylase is 10 / 215 / 400, 158, 158 / 207 / 215, 158 / 207 / 215 / 301 / 400, 158 / 207 / 215 / 400, 158 / 207 / 400, 158 / 211 / 400, 158 / 2 2. The engineered sucrose phosphorylase of claim 1, comprising at least one substitution or set of substitutions at one or more positions selected from 15 / 301 / 400, 158 / 215 / 400, 158 / 301 / 400, 158 / 400, 205, 207, 207 / 215, 207 / 215 / 400, 207 / 400, 215 / 301, 215 / 400, 242 / 400, 301, 301 / 400, and 400, wherein the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:

4.

4. The engineered sucrose phosphorylase of claim 1, comprising a polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 2 and / or 4.

5. The engineered sucrose phosphorylase according to claim 1, comprising a variant engineered sucrose phosphorylase as set forth in SEQ ID NO:

4.

6. The engineered sucrose phosphorylase according to claim 1, comprising a polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence of at least one engineered sucrose phosphorylase variant set forth in the even-numbered sequences of SEQ ID NOs: 4, 6, 24, 26, 42 to 84.

7. 2. The engineered sucrose phosphorylase of claim 1, comprising a polypeptide sequence set forth in at least one of the even-numbered sequences of SEQ ID NOs: 4, 6, 24, 26, 42-84.

8. 8. The engineered sucrose phosphorylase of any one of claims 1 to 7, further comprising at least one improved property compared to wild-type Alloscardovia omnicolens sucrose phosphorylase.

9. The improved properties include improved production of compound (1) and / or compound (3), and compound (3) is The engineered sucrose phosphorylase of claim 8,

10. The engineered sucrose phosphorylase according to any one of claims 1 to 9, which is purified.

11. 11. The engineered sucrose phosphorylase of any one of claims 1 to 10, which is part of a multienzyme system for producing nucleoside analogues.

12. A composition comprising at least one engineered sucrose phosphorylase according to any one of claims 1 to 11.

13. A polynucleotide encoding at least one engineered sucrose phosphorylase according to any one of claims 1 to 11.

14. A polynucleotide encoding at least one engineered sucrose phosphorylase, said polynucleotide comprising at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity to SEQ ID NO:1, said engineered sucrose phosphorylase comprising a polypeptide sequence, said polypeptide sequence comprising at least one substitution or set of substitutions at one or more amino acid positions in said polypeptide sequence selected from 397 and 158, said engineered sucrose phosphorylase comprising V397S, V397T, V397L, or P158R, and the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO:2, said engineered sucrose phosphorylase being selected from the wild-type Alloscardovia spp. omnicolens sucrose phosphorylase, the polynucleotide comprising an improved activity on a substrate selected from the group consisting of sucrose, sucrose-related disaccharides, and / or inorganic phosphate.

15. A polynucleotide encoding at least one engineered sucrose phosphorylase or a functional fragment thereof, comprising at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:1, wherein the engineered sucrose phosphorylase comprises a polypeptide sequence, the polypeptide sequence comprises at least one substitution or set of substitutions at one or more amino acid positions in the polypeptide sequence selected from 397 and 158, the engineered sucrose phosphorylase comprises V397S, V397T, V397L, or P158R, and the amino acid positions of the polypeptide sequence are numbered with reference to SEQ ID NO:2, and the engineered sucrose phosphorylase or a functional fragment thereof is selected from the wild-type Alloscardovia spp. omnicolens sucrose phosphorylase, the polynucleotide comprising an improved activity on a substrate selected from the group consisting of sucrose, sucrose-related disaccharides, and / or inorganic phosphate.

16. The polynucleotide according to any one of claims 13 to 15, which is operably linked to a control sequence.

17. The polynucleotide according to any one of claims 13 to 16, which is codon-optimized.

18. The polynucleotide according to any one of claims 13 to 17, comprising a polynucleotide set forth in the odd-numbered sequences of SEQ ID NOs: 3, 5, 23, 25, 41 to 83.

19. An expression vector comprising at least one polynucleotide according to any one of claims 13 to 18.

20. 20. A host cell comprising at least one expression vector according to claim 19.

21. A host cell comprising at least one polynucleotide according to any one of claims 13 to 18.

22. A method for producing an engineered sucrose phosphorylase in a host cell, comprising culturing a host cell described in claim 20 and / or 21 under suitable conditions so that at least one engineered sucrose phosphorylase is produced.

23. 23. The method of claim 22, further comprising recovering the at least one engineered sucrose phosphorylase from the culture and / or host cell.

24. 24. The method of claims 22 and / or 23, further comprising a step of purifying the at least one engineered sucrose phosphorylase.

Images